{"gene":"TNF","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1984,"finding":"Human TNF (tumour necrosis factor) was cloned and sequenced, revealing a precursor structure with ~30% amino acid homology to lymphotoxin; recombinant TNF expressed in E. coli induces haemorrhagic necrosis of transplanted sarcomas in syngeneic mice.","method":"cDNA cloning, recombinant protein expression in E. coli, in vivo tumour necrosis assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original cloning and functional reconstitution paper, foundational and highly cited","pmids":["6392892"],"is_preprint":false},{"year":1985,"finding":"TNF-α and TNF-β share a common high-affinity receptor on human cells (Kd ~0.2 nM, ~2,000 sites/cell); IFN-γ up-regulates total TNF receptor number 2–3-fold without changing affinity, explaining synergistic anti-tumour effects.","method":"125I-TNF-α radioligand binding assay, receptor characterisation on ME-180 cells, competitive displacement with unlabelled TNF-α/β and IFN-γ","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct binding assay with mutagenesis-level controls, foundational paper","pmids":["3001529"],"is_preprint":false},{"year":1990,"finding":"A TNF receptor (TNF-R, 415 aa, single-pass transmembrane) with a cysteine-rich extracellular domain homologous to the NGF receptor was cloned; transfected cells specifically bind both TNF-α and TNF-β, and the soluble serum TNF-binding protein is a proteolytic ectodomain of the same receptor.","method":"Protein purification, peptide sequencing, cDNA cloning, transfection-based binding assay with 125I-TNF-α and biotinylated TNF-α","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in transfected cells plus biochemical characterisation, foundational","pmids":["2158863"],"is_preprint":false},{"year":1995,"finding":"TRADD (34 kDa) was identified as a specific intracellular binding partner of TNFR1; overexpression of TRADD recapitulates TNF-induced apoptosis and NF-κB activation, and its C-terminal 118 aa are sufficient for both activities and for death-domain interaction with TNFR1. Caspase inhibitor CrmA suppresses TRADD-mediated cell death but not NF-κB activation, demonstrating bifurcation of these two pathways.","method":"Yeast two-hybrid, co-immunoprecipitation, overexpression in cell lines, CrmA inhibition assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods, foundational discovery, highly cited","pmids":["7758105"],"is_preprint":false},{"year":1995,"finding":"TRADD directly interacts with TRAF2 (activating NF-κB) and FADD (inducing apoptosis), defining two distinct TNFR1 signalling cascades that bifurcate at TRADD. Dominant-negative TRAF2 (lacking RING domain) blocks NF-κB but not apoptosis; dominant-negative FADD (lacking N-terminal 79 aa) blocks apoptosis but not NF-κB.","method":"Co-immunoprecipitation, dominant-negative mutant overexpression, NF-κB reporter assay, cell death assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal interaction mapping with dominant-negatives, foundational and highly cited","pmids":["8565075"],"is_preprint":false},{"year":1995,"finding":"Matrix metalloproteinases (stromelysin, matrilysin, collagenase, gelatinases) can cleave a recombinant pro-TNF substrate to yield mature TNF in vitro; broad-spectrum MMP inhibitors block pro-TNF processing and suppress serum TNF elevation after endotoxin in rats.","method":"In vitro cleavage assay with purified MMPs and recombinant pro-TNF substrate; in vivo rat endotoxin model with MMP inhibitors","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution plus in vivo pharmacological validation","pmids":["7759957"],"is_preprint":false},{"year":1997,"finding":"TACE (TNF-α-converting enzyme), a membrane-bound disintegrin metalloproteinase (ADAM17), was purified and cloned; recombinant TACE correctly processes the 26 kDa transmembrane pro-TNF-α precursor to the secreted 17 kDa mature form.","method":"Protein purification, cDNA cloning, recombinant enzyme expression, processing assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic activity with purified/recombinant TACE, foundational","pmids":["9034191"],"is_preprint":false},{"year":1998,"finding":"BRE protein was identified as an interactor of the juxtamembrane domain of p55 TNFR1 (but not p75 TNFR, Fas, or p75 neurotrophin receptor); overexpression of BRE inhibits TNF-α-induced NF-κB activation, positioning it as a modulator of TNFR1 signal transduction.","method":"Yeast two-hybrid screen, in vitro binding assay with recombinant fusion proteins, co-immunoprecipitation in transfected mammalian cells, NF-κB reporter assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — yeast two-hybrid confirmed by biochemical assay and functional NF-κB readout in single study","pmids":["9737713"],"is_preprint":false},{"year":2000,"finding":"RIP1 kinase activity (not just its scaffold function) is required for caspase-independent necrotic death downstream of Fas, TNF, and TRAIL receptors; FADD and RIP are both required for this alternative necrotic death pathway.","method":"Genetic KO primary T cells, RIP kinase-dead mutant reconstitution, caspase inhibition (zVAD), cell death morphology","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — KO plus kinase-dead mutant rescue, replicated across multiple death receptors","pmids":["11101870"],"is_preprint":false},{"year":2000,"finding":"Acetylcholine (the principal vagal neurotransmitter) significantly attenuates TNF release from LPS-stimulated human macrophages in vitro; direct electrical stimulation of the efferent vagus nerve in rats inhibits TNF synthesis in the liver and attenuates peak serum TNF during lethal endotoxaemia.","method":"In vitro macrophage stimulation assay; in vivo rodent vagus nerve electrical stimulation with ELISA measurement of serum/tissue TNF","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean in vivo intervention with defined cellular mechanism, highly cited foundational paper","pmids":["10839541"],"is_preprint":false},{"year":2000,"finding":"TNF-α inhibits thrombus formation and delays arterial occlusion in mice via a mechanism dependent on iNOS-generated nitric oxide in the vessel wall rather than direct platelet action; TNF receptor 1- and 2-deficient mice show normal thrombogenesis in the presence of TNF-α, indicating the effect is not platelet-receptor-mediated.","method":"Intravital microscopy in vivo mouse model, TNFR1/TNFR2 KO mice, iNOS KO mice, NOS inhibitor (L-NMMA), platelet aggregation and fibrinogen binding assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple KO lines plus pharmacological inhibition with defined mechanistic readout","pmids":["14617760"],"is_preprint":false},{"year":2000,"finding":"TRAF6, together with the ubiquitin-conjugating enzyme complex Ubc13/Uev1A, catalyses synthesis of K63-linked polyubiquitin chains; this K63-polyubiquitination is required for IKK activation downstream of TRAF6, establishing a non-proteolytic ubiquitin signalling role in the TNF/NF-κB pathway.","method":"Biochemical purification, peptide mass fingerprinting (MS), in vitro ubiquitination assay, proteasome inhibitor controls, IKK activation assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of ubiquitin chain synthesis with purified components, highly cited","pmids":["11057907"],"is_preprint":false},{"year":2001,"finding":"TNF-α (via TNFR2, not TNFR1) promotes proliferation of oligodendrocyte progenitors (NG2+ cells) and is required for remyelination after cuprizone-induced demyelination; TNF-α-deficient mice show significantly delayed remyelination with reduced progenitor pool and mature oligodendrocyte numbers.","method":"TNF-α, TNFR1, and TNFR2 knockout mice; cuprizone demyelination model; histology, immunohistochemistry for myelin proteins, EM morphometry, BrdU labelling","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 — genetic dissection with receptor-specific KO mice and multiple orthogonal phenotypic readouts","pmids":["11600888"],"is_preprint":false},{"year":2001,"finding":"TNF-α directly inhibits CD28 gene transcription in T cells by impairing DNA-protein complex formation at the CD28 minimal promoter initiator sequences and by causing nuclear extracts to fail activation of in vitro transcription from CD28 initiator sequences; continuous exposure generates CD4+CD28null cells.","method":"Reporter gene assay, EMSA, in vitro transcription assay, flow cytometry of surface CD28 on T cell lines/clones","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical readouts (EMSA, in vitro transcription, reporter) in single study","pmids":["11544310"],"is_preprint":false},{"year":2003,"finding":"TNFR1-induced apoptosis proceeds via two sequential complexes: membrane-bound complex I (TNFR1–TRADD–RIP1–TRAF2) rapidly activates NF-κB; TRADD and RIP1 then dissociate to form cytoplasmic complex II with FADD and caspase-8. When NF-κB activation is sufficient, FLIP(L) is incorporated into complex II and the cell survives; failure of NF-κB activation results in apoptosis via complex II.","method":"Co-immunoprecipitation of sequential complexes, NF-κB reporter assay, pharmacological NF-κB inhibition, Western blotting for FLIP(L)/caspase-8","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of sequential complexes with multiple orthogonal methods, highly cited","pmids":["12887920"],"is_preprint":false},{"year":2005,"finding":"TNF-α-induced ROS inhibit JNK-inactivating phosphatases by oxidising their catalytic cysteine to sulfenic acid, causing sustained JNK activation; sustained JNK activity is required for cytochrome c release, caspase-3 cleavage, and necrotic cell death. Mitochondrial SOD suppresses ROS accumulation, and antioxidant treatment prevents both forms of TNF-α-induced cell death.","method":"ROS measurement, phosphatase activity assay, cysteine oxidation detection, JNK activity assay, SOD overexpression, antioxidant treatment in cells and in vivo liver failure model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — mechanistic enzymology (phosphatase oxidation assay) plus genetic and pharmacological validation in cells and in vivo, highly cited","pmids":["15766528"],"is_preprint":false},{"year":2005,"finding":"A small-molecule inhibitor of TNF-α promotes trimer disassembly by forming an intermediate complex with the intact trimer at 600-fold accelerated subunit dissociation rate, ultimately yielding a dimer–inhibitor complex; X-ray crystal structure shows a single compound molecule displacing one subunit of the trimer.","method":"X-ray crystallography, biochemical dissociation kinetics, cell-based and biochemical activity assays (IC50 22 µM biochemical, 4.6 µM cellular)","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus kinetic reconstitution of mechanism","pmids":["16284179"],"is_preprint":false},{"year":2006,"finding":"Glial cells are the source of TNF-α required for homeostatic synaptic scaling in response to prolonged activity blockade; using wild-type/TNF-α-deficient neuron–glia mixed cultures, TNF-α (from glia) was shown to be necessary for scaling up AMPA receptor content at synapses, implicating glial TNF-α as a mediator of homeostatic plasticity.","method":"Mixed wild-type/TNF-α KO neuron–glia co-culture, activity blockade paradigm, AMPA receptor surface expression assay, electrophysiology (miniature EPSC amplitude)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetically defined cell-type-specific source identified with functional synaptic readout, highly cited","pmids":["16547515"],"is_preprint":false},{"year":2006,"finding":"TNF-α-induced NF-κB activation requires site-specific K63-linked polyubiquitination of RIP1 at Lys-377; RIP1(K377R) abolishes polyubiquitination and IKK/NF-κB activation, prevents recruitment of TAK1 and IKK complexes to TNFR1, and polyubiquitinated RIP1 recruits IKK via direct binding of NEMO to K63-polyubiquitin chains.","method":"In vivo ubiquitination assay, site-directed mutagenesis (K377R), co-immunoprecipitation from TNF receptor complexes, IKK kinase assay, NEMO ubiquitin-binding mutants","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis of specific ubiquitination site with biochemical reconstitution of complex assembly, highly cited","pmids":["16603398"],"is_preprint":false},{"year":2008,"finding":"TNF-α induces two distinct caspase-8 activation pathways: (1) cycloheximide-mediated (c-FLIP depletion, RIPK1-independent); (2) Smac-mimetic-mediated (cIAP1/2 autodegradation → RIPK1 release from TNFR complex → RIPK1/FADD/caspase-8 complex II, requiring CYLD deubiquitinase activity on RIPK1 K63-ubiquitin chains). Smac-mimetic pathway is not blocked by endogenous c-FLIP.","method":"Smac mimetic and cycloheximide co-treatment, RNAi knockdown of RIPK1/CYLD/cIAP1/2/c-FLIP, co-immunoprecipitation of signalling complexes, caspase-8 activity assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — systematic RNAi dissection plus co-IP of complexes across multiple conditions, highly cited","pmids":["18485876"],"is_preprint":false},{"year":2009,"finding":"RIP3 kinase is required for TNF-α-induced programmed necrosis; RIP3 expression levels correlate with necrosis susceptibility across cell lines, its kinase activity is essential, and upon necrosis induction RIP3 is recruited to RIPK1 to form a necrosis-inducing complex. RIP3 KO fibroblasts are resistant to necrosis and RIP3 KO mice are protected from tissue damage in acute pancreatitis.","method":"Genome-wide siRNA screen, RIP3 KO mice, kinase-dead mutant reconstitution, co-immunoprecipitation of necrosis complex, pancreatitis model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide screen, KO validation in vitro and in vivo, kinase-dead mutant rescue, highly cited","pmids":["19524512"],"is_preprint":false},{"year":2009,"finding":"JNK is required for TNF-α expression in hematopoietic cells but not for TNF-α-stimulated death of hepatocytes; hepatocyte-specific JNK1/2 double KO mice develop normal hepatitis, whereas hematopoietic-compartment JNK1/2 double KO mice show profound defect in hepatitis with markedly reduced TNF-α expression.","method":"Conditional (hepatocyte-specific and hematopoietic-specific) Jnk1/Jnk2 double KO mice, concanavalin A hepatitis model, TNF-α ELISA, liver damage readouts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic epistasis with clean phenotypic readout, published in Cell","pmids":["19167327"],"is_preprint":false},{"year":2011,"finding":"Rab37 small GTPase controls TNF-α secretion from macrophages; Rab37 expression is induced by LPS, overexpression of wild-type/constitutively active Rab37 increases TNF-α secretion, siRNA knockdown decreases it. Rab37 interacts with Munc13-1, and TNF-α-containing vesicles co-localise with both Rab37 and Munc13-1; Munc13-1 knockdown similarly decreases TNF-α secretion.","method":"RT-PCR, siRNA knockdown, overexpression of Rab37 mutants, LC-MS/MS interactome, immunocytochemistry, ELISA of secreted TNF-α","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 — siRNA + overexpression + co-localisation + MS interactome in single study","pmids":["21805469"],"is_preprint":false},{"year":2012,"finding":"RIP1 and RIP3 RHIM domains mediate assembly of heterodimeric filamentous β-amyloid-like structures (confirmed by ThT/Congo red binding, CD, FTIR, X-ray diffraction, solid-state NMR); the endogenous RIP1/RIP3 necrosome from necrotic cells is ultrastable and has fibrillar amyloid core structure; RHIM mutations abolish filament formation, kinase cross-activation, and programmed necrosis in vivo.","method":"Solid-state NMR, X-ray diffraction, amyloid dyes, cryo-EM, RHIM mutagenesis, in vivo necrosis assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — multiple structural methods plus mutagenesis with functional validation, highly cited","pmids":["22817896"],"is_preprint":false},{"year":2012,"finding":"MLKL (mixed lineage kinase domain-like protein) is a direct substrate and downstream effector of RIP3 in TNF-induced necroptosis; RIP3 phosphorylates MLKL at Thr357/Ser358, and these phosphorylation events are critical for necrosis; necrosulfonamide blocks necrosis by targeting MLKL downstream of RIP3.","method":"Affinity probe pull-down, co-immunoprecipitation with anti-RIP3, RNAi knockdown, phospho-site mutagenesis, small-molecule inhibitor (necrosulfonamide)","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — chemical biology probe, site-specific mutagenesis, and KD with defined mechanistic readout, highly cited","pmids":["22265413"],"is_preprint":false},{"year":2013,"finding":"Trimerized MLKL translocates to the plasma membrane during TNF-induced necroptosis via its N-terminal coiled-coil domain; plasma membrane localisation is required for Ca2+ influx, an early event of necroptosis, and TRPM7 is identified as a downstream MLKL target for Ca2+ influx.","method":"MLKL mutant overexpression, subcellular fractionation, Ca2+ flux assay, TRPM7 siRNA knockdown, co-immunoprecipitation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — domain mutagenesis, subcellular localisation assay, downstream effector identification with siRNA, highly cited","pmids":["24316671"],"is_preprint":false},{"year":2013,"finding":"Pellino3 (E3 ubiquitin ligase) targets RIP1 in a TNF-dependent manner to inhibit complex II formation and caspase-8-mediated cleavage of RIP1; Pellino3-deficient cells and mice show enhanced TNF-induced apoptosis without affecting NF-κB activation, defining Pellino3 as a regulator of the cell-death/survival balance downstream of TNF.","method":"Pellino3 siRNA/KO mice, co-immunoprecipitation of complex II, caspase-8 activity assay, TNF lethality model in vivo","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — KO mice plus co-IP of signalling complexes, but single lab","pmids":["24113711"],"is_preprint":false},{"year":2013,"finding":"Transmembrane TNF-α (tmTNF-α) on breast cancer cells can act as a reverse-signalling receptor; a monoclonal antibody targeting the membrane-retained N-terminal fragment of tmTNF-α inhibits NF-κB activation and Bcl-2 expression without activating reverse signalling, and suppresses tumour growth and metastasis in vivo.","method":"Monoclonal antibody development, in vitro ADCC assay, NF-κB/Bcl-2 Western blot, xenograft mouse model, metastasis assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo functional assays with defined molecular mechanism, single lab","pmids":["23794706"],"is_preprint":false},{"year":2018,"finding":"Transmembrane TNF-α (tmTNF-α) mediates doxorubicin resistance in breast cancer via reverse signalling through its intracellular domain, activating the ERK–GST-π axis and NF-κB anti-apoptotic pathway; NTF (N-terminal fragment retaining intracellular domain) overexpression confers DOX resistance, reversed by tmTNF-α suppression in combination with chemotherapy in a xenograft model.","method":"tmTNF-α/NTF overexpression and siRNA knockdown, Western blotting (ERK, GST-π, NF-κB), flow cytometry (apoptosis), xenograft mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway dissection in vitro validated in vivo, single lab","pmids":["29559745"],"is_preprint":false},{"year":2018,"finding":"iRhom2 regulates ADAM17 (TACE)-dependent shedding of TNF-α (and HB-EGF); iRhom2 deficiency in lupus-prone Fcgr2b−/− mice simultaneously blocks TNF-α and HB-EGF/EGFR signalling in kidney, protecting against severe lupus nephritis without altering anti-dsDNA antibody production.","method":"iRhom2 KO in Fcgr2b−/− mice, pharmacological TNF-α and EGFR blockade, unbiased transcriptome profiling of kidney/macrophages, kidney damage scoring","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with transcriptomics and pharmacological epistasis, single study","pmids":["29369823"],"is_preprint":false},{"year":2020,"finding":"Co-stimulation with TNF-α and IFN-γ, but not either cytokine alone, induces PANoptosis (inflammatory cell death combining pyroptosis, apoptosis, and necroptosis) via the JAK/STAT1/IRF1 axis, leading to nitric oxide production and caspase-8/FADD-mediated cell death; neutralising both cytokines protects mice from SARS-CoV-2 mortality, sepsis, and haemophagocytic lymphohistiocytosis.","method":"Cytokine co-treatment in cell lines, JAK/STAT1/IRF1 pathway inhibitors, caspase-8/FADD KO, iNOS inhibitor, neutralising antibody treatment in multiple in vivo mouse models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — systematic genetic and pharmacological dissection across multiple in vitro and in vivo models, highly cited","pmids":["33278357"],"is_preprint":false},{"year":2019,"finding":"Cortistatin (CST) competitively binds to both TNFR1 and TNFR2, suppressing TNF-α pro-inflammatory signalling; CST deficiency accelerates OA-like phenotype and exogenous CST attenuates OA development in vivo, with TNFR1/TNFR2 KO mice confirming TNF receptor involvement in CST's protective role.","method":"Co-immunoprecipitation, biotin-based solid-phase binding assay, TNFR1/TNFR2 KO mice, OA surgical and spontaneous models, NF-κB pathway analysis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding confirmed biochemically plus KO mouse validation, single lab","pmids":["30826358"],"is_preprint":false},{"year":2013,"finding":"EVER2 protein promotes TNF-α- and TRAIL-induced apoptosis by interacting with the N-terminal domain of TRADD, impairing recruitment of TRAF2 and RIPK1 to TRADD and thereby shifting signalling toward apoptosis; a cancer-associated EVER2 allele (I306) shows impaired TRADD binding and reduced TNF-α-induced cell death.","method":"Co-immunoprecipitation, cell death assays with TNF-α/TRAIL treatment, EVER2 overexpression/knockdown, allele-specific binding assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with functional readout and disease allele validation, single lab","pmids":["23429285"],"is_preprint":false}],"current_model":"TNF-α is synthesised as a 26 kDa transmembrane precursor that is processed to soluble 17 kDa homotrimers by the metalloprotease TACE/ADAM17 (regulated by iRhom2); trimeric TNF-α signals through TNFR1 and TNFR2 via sequential assembly of plasma-membrane complex I (TNFR1–TRADD–RIP1–TRAF2), which activates NF-κB through K63-polyubiquitination of RIP1 at Lys-377 (catalysed by TRAF6/Ubc13/Uev1A) and NEMO recruitment, and cytoplasmic complex II (TRADD–RIP1–FADD–caspase-8) which triggers apoptosis when NF-κB-dependent FLIP expression is insufficient; alternatively, when caspases are inhibited, RIP1 and RIP3 form a functional β-amyloid-like necrosome that phosphorylates MLKL, driving its trimerisation, plasma membrane translocation, Ca2+ influx via TRPM7, and necroptotic death; TNF-α-induced ROS further sustain JNK activation by oxidising JNK phosphatases, amplifying cell death; transmembrane TNF-α additionally acts as a bidirectional signalling molecule transmitting reverse signals through its intracellular domain; glia-derived TNF-α mediates homeostatic synaptic scaling, and cholinergic vagal stimulation suppresses TNF production in macrophages through an acetylcholine-mediated anti-inflammatory reflex."},"narrative":{"teleology":[{"year":1984,"claim":"Cloning of human TNF established it as a secreted protein capable of inducing hemorrhagic necrosis of tumors, resolving the molecular identity of 'tumor necrosis factor' activity known from serum studies.","evidence":"cDNA cloning, recombinant expression in E. coli, syngeneic tumor necrosis assay in mice","pmids":["6392892"],"confidence":"High","gaps":["quaternary structure unknown","receptor identity unknown","processing mechanism uncharacterized"]},{"year":1985,"claim":"Demonstration that TNF-α and TNF-β (lymphotoxin) share a common high-affinity receptor (~0.2 nM Kd) unified the two cytokines into one signaling system and showed IFN-γ synergy arises from receptor upregulation.","evidence":"125I-TNF-α radioligand binding on ME-180 cells with competitive displacement","pmids":["3001529"],"confidence":"High","gaps":["receptor molecular identity not yet cloned","intracellular signaling mechanism unknown"]},{"year":1990,"claim":"Molecular cloning of TNFR1 (415 aa, cysteine-rich extracellular domain) provided the first structural framework for understanding TNF signal transduction and revealed that soluble TNF-binding protein is its shed ectodomain.","evidence":"Protein purification, peptide sequencing, cDNA cloning, transfection-based 125I-TNF binding","pmids":["2158863"],"confidence":"High","gaps":["intracellular adaptor proteins not identified","TNFR2 not yet cloned in this study"]},{"year":1995,"claim":"Identification of TRADD as a death-domain adaptor for TNFR1, and demonstration that TRADD bifurcates signaling to TRAF2 (NF-κB) and FADD (apoptosis), established the branching logic of TNF signal transduction.","evidence":"Yeast two-hybrid, co-immunoprecipitation, dominant-negative TRAF2/FADD, CrmA inhibition","pmids":["7758105","8565075"],"confidence":"High","gaps":["ubiquitin-dependent regulatory steps not yet characterized","mechanism of NF-κB pathway suppression of death arm not defined"]},{"year":1997,"claim":"Purification and cloning of TACE/ADAM17 as the sheddase that converts 26 kDa transmembrane pro-TNF to 17 kDa soluble TNF resolved how TNF release is regulated at the post-translational level.","evidence":"Purified TACE cleaves recombinant pro-TNF; cDNA cloning confirmed disintegrin metalloproteinase identity","pmids":["9034191"],"confidence":"High","gaps":["upstream regulation of TACE (later shown via iRhom2) unknown","contribution of other proteases (MMPs) vs. TACE dominance in vivo not fully resolved"]},{"year":2000,"claim":"Multiple discoveries in 2000 expanded TNF biology beyond classical inflammatory cell death: RIP1 kinase activity was shown essential for caspase-independent necrosis; vagal acetylcholine was found to suppress macrophage TNF production (cholinergic anti-inflammatory reflex); and TRAF6/Ubc13 was shown to catalyze K63-linked polyubiquitin chains required for IKK activation.","evidence":"RIP1 KO/kinase-dead reconstitution in T cells; vagus nerve stimulation in rats with macrophage TNF ELISA; in vitro ubiquitination with purified TRAF6/Ubc13/Uev1A","pmids":["11101870","10839541","11057907"],"confidence":"High","gaps":["necrosis pathway downstream of RIP1 not mapped (RIP3, MLKL not yet known)","neurotransmitter receptor on macrophages mediating cholinergic reflex not identified","whether K63-Ub chains form on RIP1 specifically not yet shown"]},{"year":2003,"claim":"The two-complex model (membrane complex I for NF-κB, cytoplasmic complex II for apoptosis) explained how a single receptor can trigger opposing outcomes depending on NF-κB-dependent FLIP expression.","evidence":"Sequential co-immunoprecipitation of complex I and complex II, NF-κB inhibitor treatment, FLIP Western blot","pmids":["12887920"],"confidence":"High","gaps":["post-translational modifications governing complex I-to-II transition not fully defined","role of deubiquitinases in transition not yet known"]},{"year":2005,"claim":"TNF-induced ROS were shown to sustain JNK activation by oxidizing JNK phosphatase catalytic cysteines to sulfenic acid, providing a molecular mechanism for the ROS–JNK amplification loop that promotes cell death.","evidence":"Phosphatase cysteine oxidation assay, JNK activity measurement, SOD overexpression and antioxidant rescue in vitro and in hepatic failure model","pmids":["15766528"],"confidence":"High","gaps":["identity of specific phosphatases oxidized in vivo not resolved","relative contribution of ROS-JNK loop vs. direct caspase pathway not quantified"]},{"year":2006,"claim":"K63-polyubiquitination of RIP1 at Lys-377 was identified as the critical modification enabling NEMO/IKK recruitment and NF-κB activation from complex I, and glial TNF was shown to mediate homeostatic synaptic AMPA receptor scaling, extending TNF function to neural circuit homeostasis.","evidence":"RIP1 K377R mutagenesis with co-IP of TAK1/IKK; TNF KO neuron–glia co-cultures with mEPSC recordings","pmids":["16603398","16547515"],"confidence":"High","gaps":["deubiquitinase counterbalancing RIP1 K63-Ub partially addressed later by CYLD","TNF receptor subtype mediating synaptic scaling not defined"]},{"year":2008,"claim":"Smac-mimetic treatment revealed that cIAP1/2 degradation liberates RIP1, and CYLD deubiquitinase activity on RIP1 K63-Ub chains is required for RIP1-dependent complex II assembly and caspase-8 activation, distinguishing this from the classical cycloheximide-dependent apoptosis pathway.","evidence":"Systematic RNAi of RIPK1/CYLD/cIAP1/2/c-FLIP plus co-IP of signaling complexes with Smac-mimetic","pmids":["18485876"],"confidence":"High","gaps":["in vivo validation of Smac-mimetic pathway not provided","quantitative contribution of CYLD vs. other DUBs not resolved"]},{"year":2009,"claim":"RIP3 was identified as the obligate kinase partner of RIP1 for programmed necrosis, with RIP3 KO mice resistant to TNF-induced tissue damage, establishing RIP3 as the execution kinase for necroptosis.","evidence":"Genome-wide siRNA screen, RIP3 KO mice and kinase-dead reconstitution, pancreatitis model","pmids":["19524512"],"confidence":"High","gaps":["direct RIP3 substrate not yet identified (MLKL discovered later)","necrosome supramolecular structure unknown"]},{"year":2012,"claim":"The necroptosis execution pathway was completed: MLKL was identified as the direct RIP3 substrate (phosphorylated at Thr357/Ser358), and RIP1–RIP3 RHIM domains were shown to form functional β-amyloid-like filaments essential for necrosome assembly and kinase cross-activation.","evidence":"Affinity probe pull-down/phospho-site mutagenesis for MLKL; solid-state NMR, X-ray diffraction, amyloid dyes, RHIM mutagenesis for fibril structure","pmids":["22265413","22817896"],"confidence":"High","gaps":["how phospho-MLKL reaches the plasma membrane not defined","membrane permeabilization mechanism of MLKL unclear"]},{"year":2013,"claim":"Trimerized phospho-MLKL was shown to translocate to the plasma membrane via its N-terminal coiled-coil domain, where it triggers Ca²⁺ influx through TRPM7, completing the molecular pathway from necrosome to membrane disruption.","evidence":"MLKL domain mutants, subcellular fractionation, Ca²⁺ flux assay, TRPM7 siRNA","pmids":["24316671"],"confidence":"High","gaps":["whether MLKL forms pores directly or acts through TRPM7 exclusively debated","lipid-binding specificity of MLKL N-terminal domain not fully characterized"]},{"year":2018,"claim":"Transmembrane TNF was established as a bidirectional signaling molecule: its retained intracellular domain transmits reverse signals activating ERK–GST-π and NF-κB in tumor cells, and iRhom2 was identified as the upstream regulator of ADAM17-dependent TNF shedding in vivo.","evidence":"tmTNF NTF overexpression/knockdown with xenograft model; iRhom2 KO in lupus-prone mice with transcriptomic and pharmacological epistasis","pmids":["29559745","29369823"],"confidence":"Medium","gaps":["structural basis of reverse signaling through tmTNF intracellular domain unknown","iRhom2 regulation of TACE substrate selectivity not fully defined","reverse signaling findings from single laboratory"]},{"year":2020,"claim":"Co-stimulation with TNF and IFN-γ was shown to induce PANoptosis (combined pyroptosis, apoptosis, necroptosis) via JAK/STAT1/IRF1 and iNOS-dependent NO production, with dual cytokine neutralization protecting against SARS-CoV-2, sepsis, and HLH in mice.","evidence":"Cytokine co-treatment, pathway inhibitors, caspase-8/FADD KO, iNOS inhibitor, neutralizing antibodies in multiple mouse models","pmids":["33278357"],"confidence":"High","gaps":["PANoptosis concept and its distinction from sequential independent death pathways still debated","human clinical translation of dual neutralization not established"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of MLKL pore formation versus ion-channel activation at the plasma membrane; how transmembrane TNF reverse signaling is transduced through its short intracellular domain; the receptor subtype and downstream pathway mediating glial TNF-dependent synaptic scaling; and whether PANoptosis represents a mechanistically unified pathway or convergent activation of parallel death programs.","evidence":"","pmids":[],"confidence":"Low","gaps":["MLKL membrane pore versus channel activation mechanism unresolved","structural basis of tmTNF reverse signaling unknown","TNF receptor subtype for synaptic scaling not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,12,17]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,27,28,29]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,6,16]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,3,4,14,18,19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[8,14,15,19,20,23,24,25,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,12,21,30]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[17]}],"complexes":["TNFR1 complex I (TNFR1–TRADD–RIP1–TRAF2)","TNFR1 complex II (TRADD–RIP1–FADD–caspase-8)","RIP1–RIP3 necrosome"],"partners":["TNFRSF1A","TNFRSF1B","TRADD","TRAF2","RIPK1","RIPK3","ADAM17","MLKL"],"other_free_text":[]},"mechanistic_narrative":"TNF is a pleiotropic pro-inflammatory cytokine that governs cell survival, apoptosis, necroptosis, and immune activation by engaging two cognate receptors (TNFR1 and TNFR2) as a homotrimer. It is synthesized as a 26 kDa transmembrane precursor cleaved by ADAM17/TACE (regulated by iRhom2) to release the 17 kDa soluble trimer [PMID:6392892, PMID:9034191, PMID:29369823]. Ligand binding to TNFR1 nucleates membrane-proximal complex I (TNFR1–TRADD–RIP1–TRAF2), in which K63-linked polyubiquitination of RIP1 at Lys-377 recruits NEMO and TAK1 to activate NF-κB; when NF-κB-dependent FLIP expression is insufficient, TRADD and RIP1 dissociate into cytoplasmic complex II (FADD–caspase-8) to trigger apoptosis, or, when caspases are inhibited, RIP1 and RIP3 assemble an amyloid-like necrosome that phosphorylates MLKL, driving its trimerization, plasma-membrane translocation, and necroptotic Ca²⁺ influx via TRPM7 [PMID:12887920, PMID:16603398, PMID:22817896, PMID:22265413, PMID:24316671]. Beyond cell death, glial-derived TNF mediates homeostatic synaptic scaling of AMPA receptors, TNFR2 signaling promotes oligodendrocyte progenitor proliferation and remyelination, and vagal acetylcholine suppresses macrophage TNF production through a cholinergic anti-inflammatory reflex [PMID:16547515, PMID:11600888, PMID:10839541]."},"prefetch_data":{"uniprot":{"accession":"P01375","full_name":"Tumor necrosis factor","aliases":["Cachectin","TNF-alpha","Tumor necrosis factor ligand superfamily member 2","TNF-a"],"length_aa":233,"mass_kda":25.6,"function":"Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:16829952, PubMed:22517918, PubMed:23396208). Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity). Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 (PubMed:12794819). Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity) The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01375/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNF","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNF","total_profiled":1310},"omim":[{"mim_id":"621524","title":"WD REPEAT- AND SOCS BOX-CONTAINING PROTEIN 2; WSB2","url":"https://www.omim.org/entry/621524"},{"mim_id":"621234","title":"ICHAD SYNDROME; ICHAD","url":"https://www.omim.org/entry/621234"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"621030","title":"AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME, AUTOSOMAL DOMINANT; AIPDSA","url":"https://www.omim.org/entry/621030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":19.9},{"tissue":"lymphoid tissue","ntpm":6.1}],"url":"https://www.proteinatlas.org/search/TNF"},"hgnc":{"alias_symbol":["TNFSF2","DIF","TNF-alpha"],"prev_symbol":["TNFA"]},"alphafold":{"accession":"P01375","domains":[{"cath_id":"2.60.120.40","chopping":"86-231","consensus_level":"high","plddt":96.5962,"start":86,"end":231},{"cath_id":"1.20.5","chopping":"29-58","consensus_level":"medium","plddt":83.061,"start":29,"end":58}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01375","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01375-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01375-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNF","jax_strain_url":"https://www.jax.org/strain/search?query=TNF"},"sequence":{"accession":"P01375","fasta_url":"https://rest.uniprot.org/uniprotkb/P01375.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01375/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01375"}},"corpus_meta":[{"pmid":"16547515","id":"PMC_16547515","title":"Synaptic scaling mediated by glial TNF-alpha.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16547515","citation_count":1357,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18485876","id":"PMC_18485876","title":"TNF-alpha induces two distinct caspase-8 activation pathways.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18485876","citation_count":1134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11600888","id":"PMC_11600888","title":"TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.","date":"2001","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11600888","citation_count":820,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10891884","id":"PMC_10891884","title":"TNF alpha and the TNF receptor superfamily: structure-function relationship(s).","date":"2000","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/10891884","citation_count":800,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15239085","id":"PMC_15239085","title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15239085","citation_count":781,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20194223","id":"PMC_20194223","title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.","date":"2010","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20194223","citation_count":650,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23685857","id":"PMC_23685857","title":"TNF-α signalling and inflammation: interactions between old acquaintances.","date":"2013","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/23685857","citation_count":643,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19118493","id":"PMC_19118493","title":"Role of TNF-alpha in vascular dysfunction.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19118493","citation_count":551,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12951580","id":"PMC_12951580","title":"Anti-TNF-alpha therapies: the next generation.","date":"2003","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/12951580","citation_count":451,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16284179","id":"PMC_16284179","title":"Small-molecule inhibition of TNF-alpha.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16284179","citation_count":418,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24592264","id":"PMC_24592264","title":"Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24592264","citation_count":337,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18629684","id":"PMC_18629684","title":"Insulin resistance associated to obesity: the link TNF-alpha.","date":"2008","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18629684","citation_count":332,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10355025","id":"PMC_10355025","title":"The role of TNF alpha in adipocyte metabolism.","date":"1999","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10355025","citation_count":325,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15146098","id":"PMC_15146098","title":"The role of TNF-alpha in insulin resistance.","date":"2004","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/15146098","citation_count":307,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10652441","id":"PMC_10652441","title":"Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation.","date":"2000","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10652441","citation_count":304,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10320052","id":"PMC_10320052","title":"Mechanisms of TNF-alpha-induced insulin resistance.","date":"1999","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/10320052","citation_count":303,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17310002","id":"PMC_17310002","title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.","date":"2007","source":"Archives of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17310002","citation_count":268,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20173393","id":"PMC_20173393","title":"TNF-alpha and obesity.","date":"2010","source":"Current directions in autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/20173393","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7730642","id":"PMC_7730642","title":"TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7730642","citation_count":239,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11544310","id":"PMC_11544310","title":"Down-regulation of CD28 expression by TNF-alpha.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544310","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7759957","id":"PMC_7759957","title":"Matrix metalloproteinases and processing of pro-TNF-alpha.","date":"1995","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7759957","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30170620","id":"PMC_30170620","title":"Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.","date":"2018","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30170620","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21288189","id":"PMC_21288189","title":"Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.","date":"2011","source":"CNS & neurological disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21288189","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18504118","id":"PMC_18504118","title":"Depression, comorbidities and the TNF-alpha system.","date":"2008","source":"European psychiatry : the journal of the Association of European Psychiatrists","url":"https://pubmed.ncbi.nlm.nih.gov/18504118","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19620291","id":"PMC_19620291","title":"Blocking TNF-alpha attenuates aneurysm formation in a murine model.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19620291","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9917875","id":"PMC_9917875","title":"Sleep. A physiologic role for IL-1 beta and TNF-alpha.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9917875","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15110769","id":"PMC_15110769","title":"Targets for TNF-alpha-induced lipolysis in human adipocytes.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15110769","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23628802","id":"PMC_23628802","title":"Regulation of TNF-α with a focus on rheumatoid arthritis.","date":"2013","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23628802","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1777835","id":"PMC_1777835","title":"TNF alpha mRNA expression in allergic inflammation.","date":"1991","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1777835","citation_count":156,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18655773","id":"PMC_18655773","title":"Regulation of PPARgamma function by TNF-alpha.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18655773","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33053859","id":"PMC_33053859","title":"Complexity of TNF-α Signaling in Heart Disease.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33053859","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19167327","id":"PMC_19167327","title":"Induction of hepatitis by JNK-mediated expression of TNF-alpha.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19167327","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25492727","id":"PMC_25492727","title":"Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25492727","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17447161","id":"PMC_17447161","title":"TNF-alpha alters visfatin and adiponectin levels in human fat.","date":"2007","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/17447161","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15625348","id":"PMC_15625348","title":"TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad.","date":"2005","source":"QJM : monthly journal of the Association of Physicians","url":"https://pubmed.ncbi.nlm.nih.gov/15625348","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16846800","id":"PMC_16846800","title":"Modulating TNF-alpha signaling with natural products.","date":"2006","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/16846800","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19506720","id":"PMC_19506720","title":"The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology.","date":"2008","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19506720","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23794706","id":"PMC_23794706","title":"Targeting transmembrane TNF-α suppresses breast cancer growth.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23794706","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1550865","id":"PMC_1550865","title":"Genomic structure, induction, and production of TNF-alpha.","date":"1992","source":"Immunology series","url":"https://pubmed.ncbi.nlm.nih.gov/1550865","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27652081","id":"PMC_27652081","title":"TNF-α gene polymorphisms and expression.","date":"2016","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/27652081","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19277912","id":"PMC_19277912","title":"TNF-alpha and its inhibitors in cancer.","date":"2009","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19277912","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29369823","id":"PMC_29369823","title":"iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29369823","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8933152","id":"PMC_8933152","title":"TNF-alpha-induced regulation and signalling in macrophages.","date":"1996","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8933152","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14617760","id":"PMC_14617760","title":"Antithrombotic activity of TNF-alpha.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/14617760","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37691196","id":"PMC_37691196","title":"At the Crossroads of TNF α Signaling and Cancer.","date":"2024","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37691196","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20625488","id":"PMC_20625488","title":"Anti-TNF-alpha therapies in systemic lupus erythematosus.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20625488","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10201952","id":"PMC_10201952","title":"TNF-alpha regulates corneal Langerhans cell migration.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10201952","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24272709","id":"PMC_24272709","title":"Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin.","date":"2014","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/24272709","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1741931","id":"PMC_1741931","title":"Ubiquitous expression of TNF-alpha/cachectin immunoreactivity in human endometrium.","date":"1991","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/1741931","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21384095","id":"PMC_21384095","title":"Implications of TNF-α in the pathogenesis and management of GVHD.","date":"2011","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21384095","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29559745","id":"PMC_29559745","title":"Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29559745","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10940203","id":"PMC_10940203","title":"TNF-alpha/TNFRI in primary and immortalized first trimester cytotrophoblasts.","date":"2000","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/10940203","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11953838","id":"PMC_11953838","title":"TNF-alpha is involved in activating DNA fragmentation in skeletal muscle.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11953838","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28127258","id":"PMC_28127258","title":"TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/28127258","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26419478","id":"PMC_26419478","title":"TNF-α: a treatment target or cause of sarcoidosis?","date":"2015","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/26419478","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17017952","id":"PMC_17017952","title":"Anti-TNF-alpha antibody therapies in autoimmune diseases.","date":"2006","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17017952","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30826358","id":"PMC_30826358","title":"Cortistatin binds to TNF-α receptors and protects against osteoarthritis.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30826358","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27831558","id":"PMC_27831558","title":"RIPK1 protects from TNF-α-mediated liver damage during hepatitis.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27831558","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26407855","id":"PMC_26407855","title":"The multimerization and secretion of adiponectin are regulated by TNF-alpha.","date":"2015","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/26407855","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21559854","id":"PMC_21559854","title":"Role of TNF-alpha during central sensitization in preclinical studies.","date":"2011","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/21559854","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30578874","id":"PMC_30578874","title":"Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-α.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30578874","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22246057","id":"PMC_22246057","title":"IL-33 regulates TNF-α dependent effects in synovial fibroblasts.","date":"2012","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22246057","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27358858","id":"PMC_27358858","title":"TNF-α, a good or bad factor in hematological diseases?","date":"2014","source":"Stem cell investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27358858","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15621052","id":"PMC_15621052","title":"Free radicals trigger TNF alpha-induced cardioprotection.","date":"2005","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/15621052","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18693138","id":"PMC_18693138","title":"Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease.","date":"2008","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18693138","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1981213","id":"PMC_1981213","title":"Sulfasalazine inhibits the binding of TNF alpha to its receptor.","date":"1990","source":"Immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/1981213","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11889578","id":"PMC_11889578","title":"Stimulation of TNF alpha expression by hyperosmotic stress.","date":"2002","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11889578","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20870895","id":"PMC_20870895","title":"Molecular pathways of spontaneous and TNF-{alpha}-mediated neutrophil apoptosis under intermittent hypoxia.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20870895","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16487927","id":"PMC_16487927","title":"Monad, a WD40 repeat protein, promotes apoptosis induced by TNF-alpha.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16487927","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21805469","id":"PMC_21805469","title":"Release of TNF-α from macrophages is mediated by small GTPase Rab37.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21805469","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19136378","id":"PMC_19136378","title":"Infliximab and the TNF-alpha system.","date":"2009","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19136378","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24035785","id":"PMC_24035785","title":"Resveratrol enhances TNF-α production in human monocytes upon bacterial stimulation.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24035785","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23890415","id":"PMC_23890415","title":"TNF-α signaling in Fanconi anemia.","date":"2013","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23890415","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25306394","id":"PMC_25306394","title":"TNF-α promotes invasive growth through the MET signaling pathway.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25306394","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11506387","id":"PMC_11506387","title":"Targets of glucocorticoid action on TNF-alpha release by macrophages.","date":"2001","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/11506387","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11817710","id":"PMC_11817710","title":"Leptin, insulin and TNF-alpha in weight loss.","date":"2001","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11817710","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9737713","id":"PMC_9737713","title":"BRE: a modulator of TNF-alpha action.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9737713","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19020014","id":"PMC_19020014","title":"Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19020014","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26088424","id":"PMC_26088424","title":"Effects of TNF-α on Cementoblast Differentiation, Mineralization, and Apoptosis.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26088424","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19324019","id":"PMC_19324019","title":"IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19324019","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12110119","id":"PMC_12110119","title":"Perspectives for TNF-alpha-targeting therapies.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110119","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30958728","id":"PMC_30958728","title":"Targeted TNF-α Overexpression Drives Salivary Gland Inflammation.","date":"2019","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/30958728","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17902045","id":"PMC_17902045","title":"Induction of TNF-alpha by LPS in Schwann cell is regulated by MAPK activation signals.","date":"2007","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17902045","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35687009","id":"PMC_35687009","title":"TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes.","date":"2022","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35687009","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23072510","id":"PMC_23072510","title":"Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes.","date":"2012","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23072510","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17591895","id":"PMC_17591895","title":"The role of soluble TNF receptors for TNF-alpha in uveitis.","date":"2007","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/17591895","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24113711","id":"PMC_24113711","title":"Pellino3 targets RIP1 and regulates the pro-apoptotic effects of TNF-α.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24113711","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28692806","id":"PMC_28692806","title":"MicroRNA-155-3p Mediates TNF-α-Inhibited Cementoblast Differentiation.","date":"2017","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/28692806","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15853670","id":"PMC_15853670","title":"TNF(alpha) modulation of visceral and spinal sensory processing.","date":"2005","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15853670","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11105988","id":"PMC_11105988","title":"TNF-alpha, leptin, and lymphocyte function in human aging.","date":"2000","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11105988","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33135824","id":"PMC_33135824","title":"TNF-α signaling regulates RUNX1 function in endothelial cells.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33135824","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18557926","id":"PMC_18557926","title":"TNF-alpha stimulates Akt by a distinct aPKC-dependent pathway in premalignant keratinocytes.","date":"2008","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18557926","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31341915","id":"PMC_31341915","title":"Effect of TNF-α-Induced Sclerostin on Osteocytes during Orthodontic Tooth Movement.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31341915","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27062372","id":"PMC_27062372","title":"TNF-α downregulates CIDEC via MEK/ERK pathway in human adipocytes.","date":"2016","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/27062372","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15190675","id":"PMC_15190675","title":"Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases.","date":"2004","source":"Acta neurobiologiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/15190675","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29490055","id":"PMC_29490055","title":"ATF7 mediates TNF-α-induced telomere shortening.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29490055","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23429285","id":"PMC_23429285","title":"EVER2 protein binds TRADD to promote TNF-α-induced apoptosis.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23429285","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12551841","id":"PMC_12551841","title":"UV induces VEGF through a TNF-alpha independent pathway.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12551841","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17014432","id":"PMC_17014432","title":"Association of TNF-alpha genetic polymorphism with HLA DPB1*0301.","date":"2006","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17014432","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29306772","id":"PMC_29306772","title":"Interaction between BDNF and TNF-α genes in schizophrenia.","date":"2017","source":"Psychoneuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29306772","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10839541","id":"PMC_10839541","title":"Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10839541","citation_count":3164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22265413","id":"PMC_22265413","title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22265413","citation_count":2249,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12887920","id":"PMC_12887920","title":"Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12887920","citation_count":2132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19524512","id":"PMC_19524512","title":"Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19524512","citation_count":1879,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6392892","id":"PMC_6392892","title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6392892","citation_count":1793,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10604883","id":"PMC_10604883","title":"Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10604883","citation_count":1753,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7758105","id":"PMC_7758105","title":"The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7758105","citation_count":1732,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8565075","id":"PMC_8565075","title":"TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8565075","citation_count":1709,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2413547","id":"PMC_2413547","title":"Tumor necrosis factor (TNF).","date":"1985","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2413547","citation_count":1598,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11101870","id":"PMC_11101870","title":"Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.","date":"2000","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11101870","citation_count":1532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11057907","id":"PMC_11057907","title":"Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11057907","citation_count":1526,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15766528","id":"PMC_15766528","title":"Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15766528","citation_count":1506,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9034191","id":"PMC_9034191","title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9034191","citation_count":1416,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17192785","id":"PMC_17192785","title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192785","citation_count":1399,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33278357","id":"PMC_33278357","title":"Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33278357","citation_count":1359,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22945416","id":"PMC_22945416","title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.","date":"2013","source":"JAMA psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22945416","citation_count":1274,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33800290","id":"PMC_33800290","title":"The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33800290","citation_count":1223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24316671","id":"PMC_24316671","title":"Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24316671","citation_count":1109,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2158863","id":"PMC_2158863","title":"Molecular cloning and expression of a receptor for human tumor necrosis factor.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2158863","citation_count":1077,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11085990","id":"PMC_11085990","title":"Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11085990","citation_count":1058,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3001529","id":"PMC_3001529","title":"Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3001529","citation_count":1055,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7935762","id":"PMC_7935762","title":"Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7935762","citation_count":1038,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22817896","id":"PMC_22817896","title":"The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22817896","citation_count":989,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12297050","id":"PMC_12297050","title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12297050","citation_count":941,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19738171","id":"PMC_19738171","title":"Systemic inflammation and disease progression in Alzheimer disease.","date":"2009","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19738171","citation_count":887,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16603398","id":"PMC_16603398","title":"Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16603398","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45235,"output_tokens":6182,"usd":0.114217},"stage2":{"model":"claude-opus-4-6","input_tokens":10152,"output_tokens":4460,"usd":0.24339},"total_usd":0.757298,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":57125,"output_tokens":8372,"usd":0.148478},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12775,"output_tokens":4144,"usd":0.251213}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Glial-derived TNF-α mediates homeostatic synaptic scaling in response to prolonged activity blockade; glia are the cellular source of TNF-α required for this form of plasticity, which involves alterations in receptor content at synapses.\",\n      \"method\": \"Mixed cultures of wild-type and TNF-α-deficient neurons and glia; genetic loss-of-function with specific synaptic scaling readout\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular phenotype, source cell identified by cell-mixing experiment; highly cited foundational study\",\n      \"pmids\": [\"16547515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-α induces two distinct caspase-8 activation pathways: (1) cycloheximide eliminates c-FLIP, enabling caspase-8 activation independently of RIPK1; (2) Smac mimetic triggers autodegradation of cIAP1/2, releasing RIPK1 from the TNF receptor complex to form a caspase-8-activating complex (RIPK1/FADD/caspase-8), a process also requiring CYLD-mediated K63 deubiquitination of RIPK1.\",\n      \"method\": \"Cell-based apoptosis assays with small-molecule perturbations, genetic knockdowns, biochemical complex isolation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemical complex isolation, genetic KD, pharmacological perturbation), highly cited\",\n      \"pmids\": [\"18485876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-α promotes oligodendrocyte progenitor proliferation and remyelination via TNFR2 (not TNFR1); mice lacking TNF-α show delayed remyelination with reduced NG2+ progenitor pools and mature oligodendrocyte numbers.\",\n      \"method\": \"Genetic knockout mice (TNF-α-/-, TNFR1-/-, TNFR2-/-) in cuprizone demyelination model; histology, immunohistochemistry, electron microscopy, BrdU labeling\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor-specific KO lines with defined cellular phenotype, replicated by receptor-subtype dissection\",\n      \"pmids\": [\"11600888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-α binds as a trimer to two cell surface receptors: TNFR1 (55 kDa) and TNFR2 (75 kDa); crystal structures of TNF-α, TNF-β, sTNFR1, and the TNF-β/sTNFR1 complex have defined the structural basis of receptor engagement.\",\n      \"method\": \"X-ray crystallography; structural review integrating crystal structures of ligand and receptor\",\n      \"journal\": \"Microscopy research and technique\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures of TNF-α, TNF-β, and receptor complexes; foundational structural review\",\n      \"pmids\": [\"10891884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Matrix metalloproteinases (stromelysin, matrilysin, collagenase, gelatinases) can cleave a recombinant pro-TNF substrate to yield mature TNF-α; broad-spectrum MMP inhibitors prevent pro-TNF processing and reduce blood TNF-α levels after endotoxin administration in vivo.\",\n      \"method\": \"In vitro cleavage assay with purified MMPs and recombinant pro-TNF substrate; in vivo endotoxin model with MMP inhibitors\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of enzymatic cleavage plus in vivo validation\",\n      \"pmids\": [\"7759957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A small-molecule inhibitor promotes TNF-α trimer disassembly by binding an intermediate complex with the intact trimer, accelerating subunit dissociation ~600-fold; crystallography reveals the compound displaces one subunit to form a compound-dimer complex.\",\n      \"method\": \"X-ray crystallography; biochemical and cell-based inhibition assays; kinetic dissociation measurements\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in vitro reconstitution and kinetic assays\",\n      \"pmids\": [\"16284179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TNF-α mediates insulin resistance through serine phosphorylation of IRS-1, impairing insulin receptor tyrosine phosphorylation; TNF-α knockout obese mice show increased insulin-stimulated tyrosine phosphorylation of the insulin receptor in muscle and adipose tissue. The p55 receptor is more important than p75 for this effect.\",\n      \"method\": \"Genetic knockout mice (TNF-α-/-, p55-/-, p75-/-, double KO) with glucose/insulin tolerance tests; phosphorylation assays in tissue\",\n      \"journal\": \"Experimental and clinical endocrinology & diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor-specific KO lines with defined biochemical and physiological readouts\",\n      \"pmids\": [\"10320052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"JNK is required in hematopoietic cells for TNF-α expression during hepatitis; hepatocyte-specific JNK1/2 deficiency does not protect from hepatitis, whereas hematopoietic JNK1/2 deficiency markedly reduces TNF-α expression and hepatic damage.\",\n      \"method\": \"Conditional and hematopoietic-specific Jnk1/Jnk2 double-knockout mice; in vivo hepatitis model; genetic epistasis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic epistasis in vivo with defined phenotypic readout, published in Cell\",\n      \"pmids\": [\"19167327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Transmembrane TNF-α (tmTNF-α) acts as a bipolar molecule: it transmits signals as a ligand by binding TNFR1/2 on target cells, and also acts as a receptor transmitting reverse (outside-to-inside) signals back to the TNF-α-producing cell when engaged by its native receptors. TACE cleaves tmTNF-α to release the soluble form.\",\n      \"method\": \"Review integrating functional studies of reverse signaling, ligand activity, and anti-TNF agent interactions\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic synthesis from multiple functional studies; review but describes established experimental findings\",\n      \"pmids\": [\"20194223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BRE protein directly binds the juxtamembrane (cytoplasmic) domain of the p55 TNF receptor; overexpression of BRE inhibits TNF-α-induced NF-κB activation, identifying BRE as a modulator of p55 TNF receptor signal transduction.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro biochemical binding assay with recombinant fusion proteins; co-immunoprecipitation in mammalian cells; NF-κB reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction confirmed by multiple methods (Y2H + in vitro + Co-IP) plus functional reporter assay, single lab\",\n      \"pmids\": [\"9737713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Rab37, a small GTPase upregulated in macrophages by LPS, promotes TNF-α secretion; Rab37 interacts with the membrane fusion regulator Munc13-1, and TNF-α-containing vesicles co-localize with both Rab37 and Munc13-1. Knockdown of either Rab37 or Munc13-1 significantly reduces TNF-α secretion.\",\n      \"method\": \"siRNA knockdown; overexpression of constitutively active Rab37; LC-MS/MS interactome; immunocytochemistry co-localization; ELISA for TNF-α secretion\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — interactome MS plus functional KD/OE with defined secretion phenotype, single lab\",\n      \"pmids\": [\"21805469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pellino3 (E3 ubiquitin ligase) targets RIP1 in a TNF-α-dependent manner to inhibit formation of the death-inducing complex II and suppress caspase-8-mediated apoptosis; Pellino3-deficient mice show increased TNF-induced apoptosis and lethality.\",\n      \"method\": \"Pellino3-deficient mice; complex II formation assay; caspase-8 cleavage of RIP1; TNF/cycloheximide co-stimulation; genetic KO with in vivo phenotype\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO plus biochemical complex formation and caspase assays, multiple orthogonal methods\",\n      \"pmids\": [\"24113711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"iRhom2 regulates ADAM17-dependent shedding of TNF-α (and HB-EGF); iRhom2 deficiency simultaneously blocks TNF-α and EGFR signaling in the kidney, protecting lupus-prone mice from renal damage without altering anti-dsDNA antibody production.\",\n      \"method\": \"iRhom2-deficient lupus-prone mice; pharmacological blockade of TNF-α or EGFR; transcriptome profiling of kidneys; genetic epistasis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological epistasis plus transcriptomics, multiple orthogonal approaches\",\n      \"pmids\": [\"29369823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TNF-α-induced neurotoxicity is mediated through TNF-R1 (not TNF-R2); TNF-α exposure causes rapid mitochondrial dysfunction (reduced basal respiration, ATP production, maximal respiration within 1.5 h), increased caspase-8 activity, decreased mitochondrial membrane potential, and cytochrome c release.\",\n      \"method\": \"TNF-R1 and TNF-R2 antibody blockade; mitochondrial respiration assays; caspase-8 activity assay; cytochrome c fractionation; cell viability in HT-22 cells and primary neurons\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific antibody blockade plus multiple orthogonal mechanistic assays, single lab\",\n      \"pmids\": [\"25492727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Transmembrane TNF-α (tmTNF-α) promotes doxorubicin resistance in breast cancer cells via reverse signaling through the tmTNF-α/NTF-ERK-GST-π axis and tmTNF-α/NTF-NF-κB-mediated anti-apoptotic functions; overexpression of the intracellular domain-containing N-terminal fragment (NTF) of tmTNF-α is sufficient to confer resistance.\",\n      \"method\": \"tmTNF-α overexpression/knockdown; NTF mutant overexpression; pathway inhibitors; xenograft mouse model; Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific mutant plus in vivo xenograft and pathway dissection, single lab\",\n      \"pmids\": [\"29559745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TNF-α-induced lipolysis in human adipocytes is mediated by downregulation of perilipin (PLIN) expression via the p44/42 MAPK and JNK pathways; Gαi does not play a role in TNF-α-mediated lipolysis in human (unlike rodent) adipocytes.\",\n      \"method\": \"Human adipocytes treated with TNF-α ± specific MAPK inhibitors (PD98059, SP600125); PLIN and Gαi mRNA/protein quantification; pertussis toxin experiments; lipolysis assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with multiple inhibitors plus pertussis toxin controls, single lab\",\n      \"pmids\": [\"15110769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-α directly inhibits CD28 gene transcription by suppressing the activity of the CD28 minimal promoter; this involves loss of DNA-protein complex formation at initiator sequences of the CD28 gene and failure of nuclear extracts from TNF-α-treated cells to support in vitro transcription from TATA box/CD28 initiator templates.\",\n      \"method\": \"Reporter gene bioassay; electrophoretic mobility shift assay (EMSA); in vitro transcription assay; T cell line and clone culture with TNF-α\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro transcription assay plus EMSA plus reporter gene, single lab with multiple methods\",\n      \"pmids\": [\"11544310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TNF-α inhibits thrombus formation in vivo through an iNOS-dependent mechanism: systemic TNF-α decreases platelet fibrinogen binding, P-selectin expression, and aggregation; this effect is not direct on platelets but mediated by rapid NO generation in the vessel wall. TNF receptor 1- and 2-deficient mice show normal thrombogenesis under TNF-α.\",\n      \"method\": \"Intravital microscopy in mouse vascular injury model; TNF receptor KO mice; iNOS-deficient mice; NOS inhibitor (L-NAME); platelet activation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor KO lines plus iNOS KO and pharmacological NOS inhibition, in vivo mechanistic dissection\",\n      \"pmids\": [\"14617760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNF-α induces telomere shortening through phosphorylation of the transcription factor ATF7 by p38 kinase; ATF7 and telomerase are normally co-localized on telomeres via interactions with the Ku complex, and TNF-α-driven p38 activation causes release of both ATF7 and telomerase from telomeres, leading to telomere shortening.\",\n      \"method\": \"ATF7-deficient mice; chromatin immunoprecipitation showing ATF7 and telomerase on telomeres; p38 kinase phosphorylation assays; Ku complex interaction studies; telomere length measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mice plus ChIP-based localization and kinase phosphorylation assays, multiple orthogonal methods\",\n      \"pmids\": [\"29490055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EVER2 protein interacts with the N-terminal domain of TRADD, impairs recruitment of TRAF2 and RIPK1 to TRADD, and promotes TNF-α- and TRAIL-induced apoptosis; a cancer-associated EVER2 allele (I306) shows impaired TRADD interaction and reduced apoptosis in response to TNF-α.\",\n      \"method\": \"Co-immunoprecipitation; domain-mapping; cell death assays with TNF-α treatment; allele-specific functional comparison\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus domain mapping plus functional apoptosis assay with disease allele comparison, single lab\",\n      \"pmids\": [\"23429285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TNF-α mediates corneal Langerhans cell (LC) migration through both TNFR1 (p55) and TNFR2 (p75) signaling; IL-1-induced LC migration is largely dependent on TNFR function, whereas TNF-α-induced LC migration is independent of IL-1 receptor I activity.\",\n      \"method\": \"Gene-targeted knockout mice (IL-1RI-/-, p55-/-, p75-/-, double KO); corneal cautery and cytokine injection models; immunofluorescence enumeration of LC\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor-specific KO lines with defined cellular migration phenotype, genetic epistasis\",\n      \"pmids\": [\"10201952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cortistatin (CST) competitively binds to both TNFR1 and TNFR2, suppressing pro-inflammatory TNF-α function; CST-deficient mice show accelerated osteoarthritis, while exogenous CST attenuates OA development via inhibition of NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation; biotin-based solid-phase binding assay; TNFR1- and TNFR2-knockout mice; in vivo OA models; NF-κB pathway analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assays plus receptor KO mice in disease model, multiple orthogonal methods\",\n      \"pmids\": [\"30826358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TNF-α promotes invasive growth by inducing MET receptor tyrosine kinase transcription via NF-κB; MET then sustains MEK/ERK activation and Snail accumulation, leading to E-cadherin downregulation. TNF-α also induces HGF secretion by fibroblasts, creating a paracrine HGF/MET pro-invasive loop.\",\n      \"method\": \"MET-specific inhibitors (small molecules, antibodies, siRNAs); NF-κB pathway analysis; Western blot for Snail and E-cadherin; fibroblast conditioned medium experiments\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple MET inhibition strategies plus mechanistic signaling cascade dissection, single lab\",\n      \"pmids\": [\"25306394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNF-α downregulates CIDEC (lipid droplet-coating protein) in human adipocytes through the MEK/ERK pathway, which phosphorylates and causes nuclear export of PPARγ, reducing CIDEC transcription; CIDEC overexpression blocks TNF-α-induced lipolysis.\",\n      \"method\": \"MEK/ERK inhibitors; constitutively active MEK1 mutant; RNAi; immunofluorescence and subcellular fractionation for PPARγ; reporter assay for CIDEC transcription\",\n      \"journal\": \"Obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological + genetic pathway dissection plus subcellular localization and transcription reporter assay, single lab\",\n      \"pmids\": [\"27062372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNF-α-induced RUNX1 expression in retinal microvascular endothelial cells occurs via JNK activation (not NF-κB or p38/MAPK), and JNK links to RUNX1 through Activator Protein 1 (AP-1); VEGF modulates this JNK-AP-1-RUNX1 feedback loop.\",\n      \"method\": \"TNF-α pathway inhibitors (JNK, NF-κB, p38 inhibitors); RUNX1 expression quantification in HRMECs; AP-1 pathway analysis; fibrovascular membrane immunostaining from PDR patients\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with multiple inhibitors plus human tissue validation, single lab\",\n      \"pmids\": [\"33135824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Sulfasalazine inhibits TNF-α activity by blocking its binding to the cell membrane receptor, demonstrated by dose-dependent displacement of 125I-labeled TNF-α from HL60 cells.\",\n      \"method\": \"Radiolabeled (125I) TNF-α displacement assay on HL60 cells; cytotoxicity assay with recombinant TNF-α\",\n      \"journal\": \"Immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct radioligand binding displacement assay with functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"1981213\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNF-α is a homotrimeric cytokine that exists in both membrane-bound (tmTNF-α, cleaved by TACE/ADAM17 regulated by iRhom2) and soluble forms; it signals through TNFR1 and TNFR2, activating NF-κB for survival/inflammation or, via RIPK1/FADD/caspase-8 complex II (regulated by cIAP1/2, CYLD, c-FLIP, and Pellino3), triggering apoptosis; it also induces necroptosis via RIP3, promotes synaptic scaling via glial release, drives oligodendrocyte regeneration via TNFR2, induces insulin resistance through IRS-1 serine phosphorylation, and its secretion from macrophages is controlled by the Rab37/Munc13-1 vesicle trafficking machinery.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Human TNF (tumour necrosis factor) was cloned and sequenced, revealing a precursor structure with ~30% amino acid homology to lymphotoxin; recombinant TNF expressed in E. coli induces haemorrhagic necrosis of transplanted sarcomas in syngeneic mice.\",\n      \"method\": \"cDNA cloning, recombinant protein expression in E. coli, in vivo tumour necrosis assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and functional reconstitution paper, foundational and highly cited\",\n      \"pmids\": [\"6392892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"TNF-α and TNF-β share a common high-affinity receptor on human cells (Kd ~0.2 nM, ~2,000 sites/cell); IFN-γ up-regulates total TNF receptor number 2–3-fold without changing affinity, explaining synergistic anti-tumour effects.\",\n      \"method\": \"125I-TNF-α radioligand binding assay, receptor characterisation on ME-180 cells, competitive displacement with unlabelled TNF-α/β and IFN-γ\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay with mutagenesis-level controls, foundational paper\",\n      \"pmids\": [\"3001529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"A TNF receptor (TNF-R, 415 aa, single-pass transmembrane) with a cysteine-rich extracellular domain homologous to the NGF receptor was cloned; transfected cells specifically bind both TNF-α and TNF-β, and the soluble serum TNF-binding protein is a proteolytic ectodomain of the same receptor.\",\n      \"method\": \"Protein purification, peptide sequencing, cDNA cloning, transfection-based binding assay with 125I-TNF-α and biotinylated TNF-α\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in transfected cells plus biochemical characterisation, foundational\",\n      \"pmids\": [\"2158863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TRADD (34 kDa) was identified as a specific intracellular binding partner of TNFR1; overexpression of TRADD recapitulates TNF-induced apoptosis and NF-κB activation, and its C-terminal 118 aa are sufficient for both activities and for death-domain interaction with TNFR1. Caspase inhibitor CrmA suppresses TRADD-mediated cell death but not NF-κB activation, demonstrating bifurcation of these two pathways.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, overexpression in cell lines, CrmA inhibition assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods, foundational discovery, highly cited\",\n      \"pmids\": [\"7758105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TRADD directly interacts with TRAF2 (activating NF-κB) and FADD (inducing apoptosis), defining two distinct TNFR1 signalling cascades that bifurcate at TRADD. Dominant-negative TRAF2 (lacking RING domain) blocks NF-κB but not apoptosis; dominant-negative FADD (lacking N-terminal 79 aa) blocks apoptosis but not NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative mutant overexpression, NF-κB reporter assay, cell death assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal interaction mapping with dominant-negatives, foundational and highly cited\",\n      \"pmids\": [\"8565075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Matrix metalloproteinases (stromelysin, matrilysin, collagenase, gelatinases) can cleave a recombinant pro-TNF substrate to yield mature TNF in vitro; broad-spectrum MMP inhibitors block pro-TNF processing and suppress serum TNF elevation after endotoxin in rats.\",\n      \"method\": \"In vitro cleavage assay with purified MMPs and recombinant pro-TNF substrate; in vivo rat endotoxin model with MMP inhibitors\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus in vivo pharmacological validation\",\n      \"pmids\": [\"7759957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TACE (TNF-α-converting enzyme), a membrane-bound disintegrin metalloproteinase (ADAM17), was purified and cloned; recombinant TACE correctly processes the 26 kDa transmembrane pro-TNF-α precursor to the secreted 17 kDa mature form.\",\n      \"method\": \"Protein purification, cDNA cloning, recombinant enzyme expression, processing assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity with purified/recombinant TACE, foundational\",\n      \"pmids\": [\"9034191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BRE protein was identified as an interactor of the juxtamembrane domain of p55 TNFR1 (but not p75 TNFR, Fas, or p75 neurotrophin receptor); overexpression of BRE inhibits TNF-α-induced NF-κB activation, positioning it as a modulator of TNFR1 signal transduction.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding assay with recombinant fusion proteins, co-immunoprecipitation in transfected mammalian cells, NF-κB reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid confirmed by biochemical assay and functional NF-κB readout in single study\",\n      \"pmids\": [\"9737713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RIP1 kinase activity (not just its scaffold function) is required for caspase-independent necrotic death downstream of Fas, TNF, and TRAIL receptors; FADD and RIP are both required for this alternative necrotic death pathway.\",\n      \"method\": \"Genetic KO primary T cells, RIP kinase-dead mutant reconstitution, caspase inhibition (zVAD), cell death morphology\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus kinase-dead mutant rescue, replicated across multiple death receptors\",\n      \"pmids\": [\"11101870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Acetylcholine (the principal vagal neurotransmitter) significantly attenuates TNF release from LPS-stimulated human macrophages in vitro; direct electrical stimulation of the efferent vagus nerve in rats inhibits TNF synthesis in the liver and attenuates peak serum TNF during lethal endotoxaemia.\",\n      \"method\": \"In vitro macrophage stimulation assay; in vivo rodent vagus nerve electrical stimulation with ELISA measurement of serum/tissue TNF\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo intervention with defined cellular mechanism, highly cited foundational paper\",\n      \"pmids\": [\"10839541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-α inhibits thrombus formation and delays arterial occlusion in mice via a mechanism dependent on iNOS-generated nitric oxide in the vessel wall rather than direct platelet action; TNF receptor 1- and 2-deficient mice show normal thrombogenesis in the presence of TNF-α, indicating the effect is not platelet-receptor-mediated.\",\n      \"method\": \"Intravital microscopy in vivo mouse model, TNFR1/TNFR2 KO mice, iNOS KO mice, NOS inhibitor (L-NMMA), platelet aggregation and fibrinogen binding assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO lines plus pharmacological inhibition with defined mechanistic readout\",\n      \"pmids\": [\"14617760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TRAF6, together with the ubiquitin-conjugating enzyme complex Ubc13/Uev1A, catalyses synthesis of K63-linked polyubiquitin chains; this K63-polyubiquitination is required for IKK activation downstream of TRAF6, establishing a non-proteolytic ubiquitin signalling role in the TNF/NF-κB pathway.\",\n      \"method\": \"Biochemical purification, peptide mass fingerprinting (MS), in vitro ubiquitination assay, proteasome inhibitor controls, IKK activation assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of ubiquitin chain synthesis with purified components, highly cited\",\n      \"pmids\": [\"11057907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-α (via TNFR2, not TNFR1) promotes proliferation of oligodendrocyte progenitors (NG2+ cells) and is required for remyelination after cuprizone-induced demyelination; TNF-α-deficient mice show significantly delayed remyelination with reduced progenitor pool and mature oligodendrocyte numbers.\",\n      \"method\": \"TNF-α, TNFR1, and TNFR2 knockout mice; cuprizone demyelination model; histology, immunohistochemistry for myelin proteins, EM morphometry, BrdU labelling\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection with receptor-specific KO mice and multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"11600888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-α directly inhibits CD28 gene transcription in T cells by impairing DNA-protein complex formation at the CD28 minimal promoter initiator sequences and by causing nuclear extracts to fail activation of in vitro transcription from CD28 initiator sequences; continuous exposure generates CD4+CD28null cells.\",\n      \"method\": \"Reporter gene assay, EMSA, in vitro transcription assay, flow cytometry of surface CD28 on T cell lines/clones\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical readouts (EMSA, in vitro transcription, reporter) in single study\",\n      \"pmids\": [\"11544310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TNFR1-induced apoptosis proceeds via two sequential complexes: membrane-bound complex I (TNFR1–TRADD–RIP1–TRAF2) rapidly activates NF-κB; TRADD and RIP1 then dissociate to form cytoplasmic complex II with FADD and caspase-8. When NF-κB activation is sufficient, FLIP(L) is incorporated into complex II and the cell survives; failure of NF-κB activation results in apoptosis via complex II.\",\n      \"method\": \"Co-immunoprecipitation of sequential complexes, NF-κB reporter assay, pharmacological NF-κB inhibition, Western blotting for FLIP(L)/caspase-8\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of sequential complexes with multiple orthogonal methods, highly cited\",\n      \"pmids\": [\"12887920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TNF-α-induced ROS inhibit JNK-inactivating phosphatases by oxidising their catalytic cysteine to sulfenic acid, causing sustained JNK activation; sustained JNK activity is required for cytochrome c release, caspase-3 cleavage, and necrotic cell death. Mitochondrial SOD suppresses ROS accumulation, and antioxidant treatment prevents both forms of TNF-α-induced cell death.\",\n      \"method\": \"ROS measurement, phosphatase activity assay, cysteine oxidation detection, JNK activity assay, SOD overexpression, antioxidant treatment in cells and in vivo liver failure model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic enzymology (phosphatase oxidation assay) plus genetic and pharmacological validation in cells and in vivo, highly cited\",\n      \"pmids\": [\"15766528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A small-molecule inhibitor of TNF-α promotes trimer disassembly by forming an intermediate complex with the intact trimer at 600-fold accelerated subunit dissociation rate, ultimately yielding a dimer–inhibitor complex; X-ray crystal structure shows a single compound molecule displacing one subunit of the trimer.\",\n      \"method\": \"X-ray crystallography, biochemical dissociation kinetics, cell-based and biochemical activity assays (IC50 22 µM biochemical, 4.6 µM cellular)\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus kinetic reconstitution of mechanism\",\n      \"pmids\": [\"16284179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Glial cells are the source of TNF-α required for homeostatic synaptic scaling in response to prolonged activity blockade; using wild-type/TNF-α-deficient neuron–glia mixed cultures, TNF-α (from glia) was shown to be necessary for scaling up AMPA receptor content at synapses, implicating glial TNF-α as a mediator of homeostatic plasticity.\",\n      \"method\": \"Mixed wild-type/TNF-α KO neuron–glia co-culture, activity blockade paradigm, AMPA receptor surface expression assay, electrophysiology (miniature EPSC amplitude)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetically defined cell-type-specific source identified with functional synaptic readout, highly cited\",\n      \"pmids\": [\"16547515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TNF-α-induced NF-κB activation requires site-specific K63-linked polyubiquitination of RIP1 at Lys-377; RIP1(K377R) abolishes polyubiquitination and IKK/NF-κB activation, prevents recruitment of TAK1 and IKK complexes to TNFR1, and polyubiquitinated RIP1 recruits IKK via direct binding of NEMO to K63-polyubiquitin chains.\",\n      \"method\": \"In vivo ubiquitination assay, site-directed mutagenesis (K377R), co-immunoprecipitation from TNF receptor complexes, IKK kinase assay, NEMO ubiquitin-binding mutants\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis of specific ubiquitination site with biochemical reconstitution of complex assembly, highly cited\",\n      \"pmids\": [\"16603398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-α induces two distinct caspase-8 activation pathways: (1) cycloheximide-mediated (c-FLIP depletion, RIPK1-independent); (2) Smac-mimetic-mediated (cIAP1/2 autodegradation → RIPK1 release from TNFR complex → RIPK1/FADD/caspase-8 complex II, requiring CYLD deubiquitinase activity on RIPK1 K63-ubiquitin chains). Smac-mimetic pathway is not blocked by endogenous c-FLIP.\",\n      \"method\": \"Smac mimetic and cycloheximide co-treatment, RNAi knockdown of RIPK1/CYLD/cIAP1/2/c-FLIP, co-immunoprecipitation of signalling complexes, caspase-8 activity assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic RNAi dissection plus co-IP of complexes across multiple conditions, highly cited\",\n      \"pmids\": [\"18485876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RIP3 kinase is required for TNF-α-induced programmed necrosis; RIP3 expression levels correlate with necrosis susceptibility across cell lines, its kinase activity is essential, and upon necrosis induction RIP3 is recruited to RIPK1 to form a necrosis-inducing complex. RIP3 KO fibroblasts are resistant to necrosis and RIP3 KO mice are protected from tissue damage in acute pancreatitis.\",\n      \"method\": \"Genome-wide siRNA screen, RIP3 KO mice, kinase-dead mutant reconstitution, co-immunoprecipitation of necrosis complex, pancreatitis model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide screen, KO validation in vitro and in vivo, kinase-dead mutant rescue, highly cited\",\n      \"pmids\": [\"19524512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"JNK is required for TNF-α expression in hematopoietic cells but not for TNF-α-stimulated death of hepatocytes; hepatocyte-specific JNK1/2 double KO mice develop normal hepatitis, whereas hematopoietic-compartment JNK1/2 double KO mice show profound defect in hepatitis with markedly reduced TNF-α expression.\",\n      \"method\": \"Conditional (hepatocyte-specific and hematopoietic-specific) Jnk1/Jnk2 double KO mice, concanavalin A hepatitis model, TNF-α ELISA, liver damage readouts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic epistasis with clean phenotypic readout, published in Cell\",\n      \"pmids\": [\"19167327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Rab37 small GTPase controls TNF-α secretion from macrophages; Rab37 expression is induced by LPS, overexpression of wild-type/constitutively active Rab37 increases TNF-α secretion, siRNA knockdown decreases it. Rab37 interacts with Munc13-1, and TNF-α-containing vesicles co-localise with both Rab37 and Munc13-1; Munc13-1 knockdown similarly decreases TNF-α secretion.\",\n      \"method\": \"RT-PCR, siRNA knockdown, overexpression of Rab37 mutants, LC-MS/MS interactome, immunocytochemistry, ELISA of secreted TNF-α\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — siRNA + overexpression + co-localisation + MS interactome in single study\",\n      \"pmids\": [\"21805469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RIP1 and RIP3 RHIM domains mediate assembly of heterodimeric filamentous β-amyloid-like structures (confirmed by ThT/Congo red binding, CD, FTIR, X-ray diffraction, solid-state NMR); the endogenous RIP1/RIP3 necrosome from necrotic cells is ultrastable and has fibrillar amyloid core structure; RHIM mutations abolish filament formation, kinase cross-activation, and programmed necrosis in vivo.\",\n      \"method\": \"Solid-state NMR, X-ray diffraction, amyloid dyes, cryo-EM, RHIM mutagenesis, in vivo necrosis assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods plus mutagenesis with functional validation, highly cited\",\n      \"pmids\": [\"22817896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MLKL (mixed lineage kinase domain-like protein) is a direct substrate and downstream effector of RIP3 in TNF-induced necroptosis; RIP3 phosphorylates MLKL at Thr357/Ser358, and these phosphorylation events are critical for necrosis; necrosulfonamide blocks necrosis by targeting MLKL downstream of RIP3.\",\n      \"method\": \"Affinity probe pull-down, co-immunoprecipitation with anti-RIP3, RNAi knockdown, phospho-site mutagenesis, small-molecule inhibitor (necrosulfonamide)\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — chemical biology probe, site-specific mutagenesis, and KD with defined mechanistic readout, highly cited\",\n      \"pmids\": [\"22265413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Trimerized MLKL translocates to the plasma membrane during TNF-induced necroptosis via its N-terminal coiled-coil domain; plasma membrane localisation is required for Ca2+ influx, an early event of necroptosis, and TRPM7 is identified as a downstream MLKL target for Ca2+ influx.\",\n      \"method\": \"MLKL mutant overexpression, subcellular fractionation, Ca2+ flux assay, TRPM7 siRNA knockdown, co-immunoprecipitation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis, subcellular localisation assay, downstream effector identification with siRNA, highly cited\",\n      \"pmids\": [\"24316671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pellino3 (E3 ubiquitin ligase) targets RIP1 in a TNF-dependent manner to inhibit complex II formation and caspase-8-mediated cleavage of RIP1; Pellino3-deficient cells and mice show enhanced TNF-induced apoptosis without affecting NF-κB activation, defining Pellino3 as a regulator of the cell-death/survival balance downstream of TNF.\",\n      \"method\": \"Pellino3 siRNA/KO mice, co-immunoprecipitation of complex II, caspase-8 activity assay, TNF lethality model in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice plus co-IP of signalling complexes, but single lab\",\n      \"pmids\": [\"24113711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Transmembrane TNF-α (tmTNF-α) on breast cancer cells can act as a reverse-signalling receptor; a monoclonal antibody targeting the membrane-retained N-terminal fragment of tmTNF-α inhibits NF-κB activation and Bcl-2 expression without activating reverse signalling, and suppresses tumour growth and metastasis in vivo.\",\n      \"method\": \"Monoclonal antibody development, in vitro ADCC assay, NF-κB/Bcl-2 Western blot, xenograft mouse model, metastasis assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional assays with defined molecular mechanism, single lab\",\n      \"pmids\": [\"23794706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Transmembrane TNF-α (tmTNF-α) mediates doxorubicin resistance in breast cancer via reverse signalling through its intracellular domain, activating the ERK–GST-π axis and NF-κB anti-apoptotic pathway; NTF (N-terminal fragment retaining intracellular domain) overexpression confers DOX resistance, reversed by tmTNF-α suppression in combination with chemotherapy in a xenograft model.\",\n      \"method\": \"tmTNF-α/NTF overexpression and siRNA knockdown, Western blotting (ERK, GST-π, NF-κB), flow cytometry (apoptosis), xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection in vitro validated in vivo, single lab\",\n      \"pmids\": [\"29559745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"iRhom2 regulates ADAM17 (TACE)-dependent shedding of TNF-α (and HB-EGF); iRhom2 deficiency in lupus-prone Fcgr2b−/− mice simultaneously blocks TNF-α and HB-EGF/EGFR signalling in kidney, protecting against severe lupus nephritis without altering anti-dsDNA antibody production.\",\n      \"method\": \"iRhom2 KO in Fcgr2b−/− mice, pharmacological TNF-α and EGFR blockade, unbiased transcriptome profiling of kidney/macrophages, kidney damage scoring\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with transcriptomics and pharmacological epistasis, single study\",\n      \"pmids\": [\"29369823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Co-stimulation with TNF-α and IFN-γ, but not either cytokine alone, induces PANoptosis (inflammatory cell death combining pyroptosis, apoptosis, and necroptosis) via the JAK/STAT1/IRF1 axis, leading to nitric oxide production and caspase-8/FADD-mediated cell death; neutralising both cytokines protects mice from SARS-CoV-2 mortality, sepsis, and haemophagocytic lymphohistiocytosis.\",\n      \"method\": \"Cytokine co-treatment in cell lines, JAK/STAT1/IRF1 pathway inhibitors, caspase-8/FADD KO, iNOS inhibitor, neutralising antibody treatment in multiple in vivo mouse models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic genetic and pharmacological dissection across multiple in vitro and in vivo models, highly cited\",\n      \"pmids\": [\"33278357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cortistatin (CST) competitively binds to both TNFR1 and TNFR2, suppressing TNF-α pro-inflammatory signalling; CST deficiency accelerates OA-like phenotype and exogenous CST attenuates OA development in vivo, with TNFR1/TNFR2 KO mice confirming TNF receptor involvement in CST's protective role.\",\n      \"method\": \"Co-immunoprecipitation, biotin-based solid-phase binding assay, TNFR1/TNFR2 KO mice, OA surgical and spontaneous models, NF-κB pathway analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed biochemically plus KO mouse validation, single lab\",\n      \"pmids\": [\"30826358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EVER2 protein promotes TNF-α- and TRAIL-induced apoptosis by interacting with the N-terminal domain of TRADD, impairing recruitment of TRAF2 and RIPK1 to TRADD and thereby shifting signalling toward apoptosis; a cancer-associated EVER2 allele (I306) shows impaired TRADD binding and reduced TNF-α-induced cell death.\",\n      \"method\": \"Co-immunoprecipitation, cell death assays with TNF-α/TRAIL treatment, EVER2 overexpression/knockdown, allele-specific binding assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with functional readout and disease allele validation, single lab\",\n      \"pmids\": [\"23429285\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNF-α is synthesised as a 26 kDa transmembrane precursor that is processed to soluble 17 kDa homotrimers by the metalloprotease TACE/ADAM17 (regulated by iRhom2); trimeric TNF-α signals through TNFR1 and TNFR2 via sequential assembly of plasma-membrane complex I (TNFR1–TRADD–RIP1–TRAF2), which activates NF-κB through K63-polyubiquitination of RIP1 at Lys-377 (catalysed by TRAF6/Ubc13/Uev1A) and NEMO recruitment, and cytoplasmic complex II (TRADD–RIP1–FADD–caspase-8) which triggers apoptosis when NF-κB-dependent FLIP expression is insufficient; alternatively, when caspases are inhibited, RIP1 and RIP3 form a functional β-amyloid-like necrosome that phosphorylates MLKL, driving its trimerisation, plasma membrane translocation, Ca2+ influx via TRPM7, and necroptotic death; TNF-α-induced ROS further sustain JNK activation by oxidising JNK phosphatases, amplifying cell death; transmembrane TNF-α additionally acts as a bidirectional signalling molecule transmitting reverse signals through its intracellular domain; glia-derived TNF-α mediates homeostatic synaptic scaling, and cholinergic vagal stimulation suppresses TNF production in macrophages through an acetylcholine-mediated anti-inflammatory reflex.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNF is a pleiotropic pro-inflammatory cytokine that functions as a homotrimer to regulate inflammation, cell death, immune cell trafficking, metabolic homeostasis, and synaptic plasticity. The membrane-bound precursor (tmTNF-α) is cleaved by ADAM17/TACE—regulated by iRhom2—and by matrix metalloproteinases to release soluble TNF-α, while tmTNF-α itself acts as both a ligand and a receptor capable of reverse signaling [PMID:29559745, PMID:7759957, PMID:29490823, PMID:20194223]. TNF-α signals through TNFR1 to activate NF-κB-dependent survival and inflammatory gene expression or, upon loss of cIAP1/2-mediated RIPK1 ubiquitination and CYLD-dependent deubiquitination, RIPK1 is released to form a FADD/caspase-8 death-inducing complex II that triggers apoptosis—a process negatively regulated by c-FLIP and the E3 ligase Pellino3 [PMID:18485876, PMID:24113711]. Beyond canonical inflammation, TNF-α mediates insulin resistance via IRS-1 serine phosphorylation through TNFR1 (p55), drives oligodendrocyte progenitor proliferation and remyelination through TNFR2, promotes homeostatic synaptic scaling when released from glia, and induces telomere shortening through p38-mediated phosphorylation of ATF7 [PMID:10320052, PMID:11600888, PMID:16547515, PMID:29490055].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that TNF-α acts through a specific cell-surface receptor established the ligand–receptor paradigm for TNF signaling, enabling pharmacological interference at the binding step.\",\n      \"evidence\": \"Radiolabeled TNF-α displacement assay on HL60 cells showing sulfasalazine blocks receptor binding\",\n      \"pmids\": [\"1981213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity and specificity of the receptor were not resolved\", \"Single pharmacological agent without genetic confirmation\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying matrix metalloproteinases as enzymes that cleave pro-TNF to mature soluble TNF-α established that regulated proteolysis controls TNF bioavailability, opening the concept of shedding as a signaling switch.\",\n      \"evidence\": \"In vitro reconstitution of pro-TNF cleavage by purified MMPs plus in vivo MMP inhibitor reduction of serum TNF-α after endotoxin challenge\",\n      \"pmids\": [\"7759957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of MMPs versus TACE/ADAM17 in physiological shedding was unresolved\", \"Cell-type specificity of MMP-mediated processing not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery of BRE as a direct binding partner of the p55 TNFR1 cytoplasmic domain that inhibits NF-κB activation revealed that receptor-proximal adaptor binding modulates the NF-κB versus death switch.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding, co-immunoprecipitation, and NF-κB reporter assay in mammalian cells\",\n      \"pmids\": [\"9737713\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of BRE interaction not tested in vivo\", \"Mechanism by which BRE inhibits NF-κB not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic dissection in receptor-specific knockouts established that TNFR1 (p55) is the dominant receptor mediating TNF-α-induced insulin resistance via IRS-1 serine phosphorylation, linking TNF to metabolic disease.\",\n      \"evidence\": \"TNF-α−/−, p55−/−, p75−/−, and double KO mice with glucose/insulin tolerance tests and tissue phosphorylation assays\",\n      \"pmids\": [\"10320052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific kinase(s) phosphorylating IRS-1 downstream of TNFR1 not identified\", \"Contribution of TNF to human insulin resistance in vivo not directly tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that TNF-α drives corneal Langerhans cell migration through both TNFR1 and TNFR2, and that IL-1-induced migration depends on TNF receptor function, positioned TNF as a master regulator of immune cell trafficking with receptor-specific redundancy.\",\n      \"evidence\": \"IL-1RI−/−, p55−/−, p75−/−, and double KO mice in corneal cautery and cytokine injection models\",\n      \"pmids\": [\"10201952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling mediators of LC migration not identified\", \"Whether findings generalize beyond corneal tissue not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Crystal structures of TNF-α, TNF-β, sTNFR1, and the TNF-β/sTNFR1 complex defined the trimeric architecture and receptor engagement geometry, providing the structural framework for understanding all subsequent signaling and inhibitor studies.\",\n      \"evidence\": \"X-ray crystallography of ligand and receptor complexes\",\n      \"pmids\": [\"10891884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length transmembrane receptor complex structure not obtained\", \"Structural basis for differential TNFR1 vs. TNFR2 signaling outcomes not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that TNFR2—not TNFR1—mediates oligodendrocyte progenitor proliferation and remyelination established a receptor-specific protective role for TNF in the CNS, explaining why pan-TNF blockade can worsen demyelinating disease.\",\n      \"evidence\": \"TNF-α−/−, TNFR1−/−, and TNFR2−/− mice in cuprizone demyelination model with BrdU labeling and electron microscopy\",\n      \"pmids\": [\"11600888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TNFR2-downstream signaling pathway in oligodendrocyte progenitors not mapped\", \"Whether tmTNF or soluble TNF preferentially engages TNFR2 in this context not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealing that TNF-α inhibits thrombus formation indirectly via iNOS-dependent NO production in the vessel wall—rather than acting on platelets—established TNF as an anticoagulant cytokine acting through vascular endothelium.\",\n      \"evidence\": \"Intravital microscopy with TNFR1/R2 KO and iNOS KO mice plus NOS inhibitor L-NAME in vascular injury model\",\n      \"pmids\": [\"14617760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type producing NO (endothelial vs. smooth muscle) not pinpointed\", \"Relevance to human thrombotic disease not directly tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying p44/42 MAPK and JNK as mediators of TNF-α-induced perilipin downregulation and lipolysis in human adipocytes clarified the kinase cascades linking TNF to lipid mobilization.\",\n      \"evidence\": \"TNF-α treatment of human adipocytes with specific MAPK inhibitors and lipolysis quantification\",\n      \"pmids\": [\"15110769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation targets on PLIN promoter regulators not identified\", \"Single pharmacological approach without genetic confirmation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"A co-crystal structure showing a small molecule displacing one TNF-α subunit from the trimer demonstrated that trimer stability is a druggable vulnerability, establishing a new therapeutic paradigm distinct from receptor blockade.\",\n      \"evidence\": \"X-ray crystallography of compound-dimer complex plus kinetic dissociation measurements showing ~600-fold acceleration\",\n      \"pmids\": [\"16284179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of trimer-disrupting compounds not demonstrated\", \"Whether trimer disruption affects tmTNF signaling not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Proving that glia—not neurons—are the cellular source of TNF-α required for homeostatic synaptic scaling established TNF as a gliotransmitter governing neural circuit homeostasis.\",\n      \"evidence\": \"Mixed cultures of wild-type and TNF-α-deficient neurons and glia with synaptic scaling readouts\",\n      \"pmids\": [\"16547515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of TNF receptors and downstream cascades mediating AMPA receptor insertion not defined\", \"In vivo relevance to circuit-level plasticity not fully established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Biochemical isolation of the RIPK1/FADD/caspase-8 complex II and demonstration that its formation requires cIAP1/2 degradation and CYLD-mediated RIPK1 deubiquitination resolved how TNF toggles between NF-κB survival and apoptotic death.\",\n      \"evidence\": \"Cell-based apoptosis assays with Smac mimetics and cycloheximide, genetic knockdowns of CYLD/RIPK1, and biochemical complex isolation\",\n      \"pmids\": [\"18485876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics and stoichiometry of complex I-to-complex II transition not quantified\", \"How necroptosis decision branch diverges from apoptosis at this step not yet defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Cell-type-specific JNK knockouts showed that hematopoietic JNK1/2 controls TNF-α expression during hepatitis, establishing JNK as a critical transcriptional regulator of TNF production in myeloid cells.\",\n      \"evidence\": \"Hematopoietic-specific Jnk1/Jnk2 double-KO mice in ConA hepatitis model\",\n      \"pmids\": [\"19167327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct JNK target transcription factors on the TNF promoter not identified in this system\", \"Whether JNK regulation of TNF is generalizable beyond hepatitis not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery that Rab37 and its effector Munc13-1 co-localize with TNF-α-containing vesicles and are required for TNF-α secretion from macrophages identified the vesicle trafficking machinery controlling TNF release.\",\n      \"evidence\": \"siRNA knockdown and overexpression of constitutively active Rab37; LC-MS/MS interactome; ELISA for secretion\",\n      \"pmids\": [\"21805469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Rab37/Munc13-1 pathway operates in vivo not tested\", \"Other cargo of the Rab37-positive vesicle not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Pellino3 was shown to ubiquitinate RIPK1 to prevent complex II assembly, adding a key negative checkpoint that limits TNF-induced apoptosis—Pellino3-deficient mice die from TNF hypersensitivity.\",\n      \"evidence\": \"Pellino3-KO mice; complex II formation assay; caspase-8 cleavage assay upon TNF/cycloheximide\",\n      \"pmids\": [\"24113711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin linkage type deposited by Pellino3 on RIPK1 not specified\", \"Relationship between Pellino3 and cIAP1/2-mediated RIPK1 ubiquitination not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that TNF-α-mediated neurotoxicity proceeds through TNFR1-dependent mitochondrial dysfunction and caspase-8 activation distinguished the receptor-specific death pathway in neurons from the TNFR2-dependent protective pathway in oligodendrocytes.\",\n      \"evidence\": \"TNFR1/TNFR2 blocking antibodies with mitochondrial respiration, caspase-8, and cytochrome c assays in HT-22 cells and primary neurons\",\n      \"pmids\": [\"25492727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking caspase-8 to rapid mitochondrial dysfunction unclear\", \"Single cell line plus primary neurons without in vivo validation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that iRhom2 controls ADAM17-dependent TNF-α shedding in vivo and that its loss simultaneously blocks TNF and EGFR signaling to protect from lupus nephritis established iRhom2 as a proximal regulator of the soluble TNF axis in disease.\",\n      \"evidence\": \"iRhom2-deficient lupus-prone mice; pharmacological blockade of TNF-α or EGFR; kidney transcriptomics\",\n      \"pmids\": [\"29369823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether iRhom2 regulation is tissue-specific not resolved\", \"Structural basis of iRhom2–ADAM17 interaction not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"TNF-α was shown to cause telomere shortening through p38-mediated phosphorylation of ATF7, which releases ATF7 and telomerase from Ku-complex-bound telomeres, connecting chronic inflammation to replicative aging.\",\n      \"evidence\": \"ATF7-KO mice; ChIP for ATF7 and telomerase on telomeres; p38 kinase assays; telomere length measurement\",\n      \"pmids\": [\"29490055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism operates in human cells not demonstrated\", \"Kinetics of telomere shortening relative to TNF exposure duration not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Transmembrane TNF-α was shown to confer doxorubicin resistance via reverse signaling through its N-terminal intracellular fragment, activating ERK-GST-π and NF-κB anti-apoptotic programs in breast cancer cells.\",\n      \"evidence\": \"tmTNF-α and NTF mutant overexpression/knockdown; pathway inhibitors; xenograft model\",\n      \"pmids\": [\"29559745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How NTF is generated from tmTNF during reverse signaling not defined\", \"Whether reverse signaling operates in non-cancer contexts not established\", \"Single lab finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for differential TNFR1/TNFR2 signaling outcomes, the precise mechanism of complex I-to-complex II transition kinetics, how reverse signaling through tmTNF is initiated and regulated, and whether the Rab37/Munc13-1 secretory pathway operates in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full-length TNF–TNFR signaling complex structure not solved\", \"In vivo validation of Rab37-dependent TNF secretion pathway lacking\", \"Structural basis for tmTNF reverse signaling unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 3, 6, 8, 22]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 8, 14, 25]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 5, 10]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 11, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 9, 11, 18, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 11, 13, 19]}\n    ],\n    \"complexes\": [\n      \"TNF-α homotrimer\"\n    ],\n    \"partners\": [\n      \"TNFRSF1A\",\n      \"TNFRSF1B\",\n      \"RIPK1\",\n      \"FADD\",\n      \"TRADD\",\n      \"ADAM17\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TNF is a pleiotropic pro-inflammatory cytokine that governs cell survival, apoptosis, necroptosis, and immune activation by engaging two cognate receptors (TNFR1 and TNFR2) as a homotrimer. It is synthesized as a 26 kDa transmembrane precursor cleaved by ADAM17/TACE (regulated by iRhom2) to release the 17 kDa soluble trimer [PMID:6392892, PMID:9034191, PMID:29369823]. Ligand binding to TNFR1 nucleates membrane-proximal complex I (TNFR1–TRADD–RIP1–TRAF2), in which K63-linked polyubiquitination of RIP1 at Lys-377 recruits NEMO and TAK1 to activate NF-κB; when NF-κB-dependent FLIP expression is insufficient, TRADD and RIP1 dissociate into cytoplasmic complex II (FADD–caspase-8) to trigger apoptosis, or, when caspases are inhibited, RIP1 and RIP3 assemble an amyloid-like necrosome that phosphorylates MLKL, driving its trimerization, plasma-membrane translocation, and necroptotic Ca²⁺ influx via TRPM7 [PMID:12887920, PMID:16603398, PMID:22817896, PMID:22265413, PMID:24316671]. Beyond cell death, glial-derived TNF mediates homeostatic synaptic scaling of AMPA receptors, TNFR2 signaling promotes oligodendrocyte progenitor proliferation and remyelination, and vagal acetylcholine suppresses macrophage TNF production through a cholinergic anti-inflammatory reflex [PMID:16547515, PMID:11600888, PMID:10839541].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Cloning of human TNF established it as a secreted protein capable of inducing hemorrhagic necrosis of tumors, resolving the molecular identity of 'tumor necrosis factor' activity known from serum studies.\",\n      \"evidence\": \"cDNA cloning, recombinant expression in E. coli, syngeneic tumor necrosis assay in mice\",\n      \"pmids\": [\"6392892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"quaternary structure unknown\", \"receptor identity unknown\", \"processing mechanism uncharacterized\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Demonstration that TNF-α and TNF-β (lymphotoxin) share a common high-affinity receptor (~0.2 nM Kd) unified the two cytokines into one signaling system and showed IFN-γ synergy arises from receptor upregulation.\",\n      \"evidence\": \"125I-TNF-α radioligand binding on ME-180 cells with competitive displacement\",\n      \"pmids\": [\"3001529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"receptor molecular identity not yet cloned\", \"intracellular signaling mechanism unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Molecular cloning of TNFR1 (415 aa, cysteine-rich extracellular domain) provided the first structural framework for understanding TNF signal transduction and revealed that soluble TNF-binding protein is its shed ectodomain.\",\n      \"evidence\": \"Protein purification, peptide sequencing, cDNA cloning, transfection-based 125I-TNF binding\",\n      \"pmids\": [\"2158863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"intracellular adaptor proteins not identified\", \"TNFR2 not yet cloned in this study\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of TRADD as a death-domain adaptor for TNFR1, and demonstration that TRADD bifurcates signaling to TRAF2 (NF-κB) and FADD (apoptosis), established the branching logic of TNF signal transduction.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, dominant-negative TRAF2/FADD, CrmA inhibition\",\n      \"pmids\": [\"7758105\", \"8565075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ubiquitin-dependent regulatory steps not yet characterized\", \"mechanism of NF-κB pathway suppression of death arm not defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Purification and cloning of TACE/ADAM17 as the sheddase that converts 26 kDa transmembrane pro-TNF to 17 kDa soluble TNF resolved how TNF release is regulated at the post-translational level.\",\n      \"evidence\": \"Purified TACE cleaves recombinant pro-TNF; cDNA cloning confirmed disintegrin metalloproteinase identity\",\n      \"pmids\": [\"9034191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"upstream regulation of TACE (later shown via iRhom2) unknown\", \"contribution of other proteases (MMPs) vs. TACE dominance in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Multiple discoveries in 2000 expanded TNF biology beyond classical inflammatory cell death: RIP1 kinase activity was shown essential for caspase-independent necrosis; vagal acetylcholine was found to suppress macrophage TNF production (cholinergic anti-inflammatory reflex); and TRAF6/Ubc13 was shown to catalyze K63-linked polyubiquitin chains required for IKK activation.\",\n      \"evidence\": \"RIP1 KO/kinase-dead reconstitution in T cells; vagus nerve stimulation in rats with macrophage TNF ELISA; in vitro ubiquitination with purified TRAF6/Ubc13/Uev1A\",\n      \"pmids\": [\"11101870\", \"10839541\", \"11057907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"necrosis pathway downstream of RIP1 not mapped (RIP3, MLKL not yet known)\", \"neurotransmitter receptor on macrophages mediating cholinergic reflex not identified\", \"whether K63-Ub chains form on RIP1 specifically not yet shown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The two-complex model (membrane complex I for NF-κB, cytoplasmic complex II for apoptosis) explained how a single receptor can trigger opposing outcomes depending on NF-κB-dependent FLIP expression.\",\n      \"evidence\": \"Sequential co-immunoprecipitation of complex I and complex II, NF-κB inhibitor treatment, FLIP Western blot\",\n      \"pmids\": [\"12887920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"post-translational modifications governing complex I-to-II transition not fully defined\", \"role of deubiquitinases in transition not yet known\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"TNF-induced ROS were shown to sustain JNK activation by oxidizing JNK phosphatase catalytic cysteines to sulfenic acid, providing a molecular mechanism for the ROS–JNK amplification loop that promotes cell death.\",\n      \"evidence\": \"Phosphatase cysteine oxidation assay, JNK activity measurement, SOD overexpression and antioxidant rescue in vitro and in hepatic failure model\",\n      \"pmids\": [\"15766528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of specific phosphatases oxidized in vivo not resolved\", \"relative contribution of ROS-JNK loop vs. direct caspase pathway not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"K63-polyubiquitination of RIP1 at Lys-377 was identified as the critical modification enabling NEMO/IKK recruitment and NF-κB activation from complex I, and glial TNF was shown to mediate homeostatic synaptic AMPA receptor scaling, extending TNF function to neural circuit homeostasis.\",\n      \"evidence\": \"RIP1 K377R mutagenesis with co-IP of TAK1/IKK; TNF KO neuron–glia co-cultures with mEPSC recordings\",\n      \"pmids\": [\"16603398\", \"16547515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"deubiquitinase counterbalancing RIP1 K63-Ub partially addressed later by CYLD\", \"TNF receptor subtype mediating synaptic scaling not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Smac-mimetic treatment revealed that cIAP1/2 degradation liberates RIP1, and CYLD deubiquitinase activity on RIP1 K63-Ub chains is required for RIP1-dependent complex II assembly and caspase-8 activation, distinguishing this from the classical cycloheximide-dependent apoptosis pathway.\",\n      \"evidence\": \"Systematic RNAi of RIPK1/CYLD/cIAP1/2/c-FLIP plus co-IP of signaling complexes with Smac-mimetic\",\n      \"pmids\": [\"18485876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"in vivo validation of Smac-mimetic pathway not provided\", \"quantitative contribution of CYLD vs. other DUBs not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"RIP3 was identified as the obligate kinase partner of RIP1 for programmed necrosis, with RIP3 KO mice resistant to TNF-induced tissue damage, establishing RIP3 as the execution kinase for necroptosis.\",\n      \"evidence\": \"Genome-wide siRNA screen, RIP3 KO mice and kinase-dead reconstitution, pancreatitis model\",\n      \"pmids\": [\"19524512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct RIP3 substrate not yet identified (MLKL discovered later)\", \"necrosome supramolecular structure unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The necroptosis execution pathway was completed: MLKL was identified as the direct RIP3 substrate (phosphorylated at Thr357/Ser358), and RIP1–RIP3 RHIM domains were shown to form functional β-amyloid-like filaments essential for necrosome assembly and kinase cross-activation.\",\n      \"evidence\": \"Affinity probe pull-down/phospho-site mutagenesis for MLKL; solid-state NMR, X-ray diffraction, amyloid dyes, RHIM mutagenesis for fibril structure\",\n      \"pmids\": [\"22265413\", \"22817896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how phospho-MLKL reaches the plasma membrane not defined\", \"membrane permeabilization mechanism of MLKL unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Trimerized phospho-MLKL was shown to translocate to the plasma membrane via its N-terminal coiled-coil domain, where it triggers Ca²⁺ influx through TRPM7, completing the molecular pathway from necrosome to membrane disruption.\",\n      \"evidence\": \"MLKL domain mutants, subcellular fractionation, Ca²⁺ flux assay, TRPM7 siRNA\",\n      \"pmids\": [\"24316671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether MLKL forms pores directly or acts through TRPM7 exclusively debated\", \"lipid-binding specificity of MLKL N-terminal domain not fully characterized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Transmembrane TNF was established as a bidirectional signaling molecule: its retained intracellular domain transmits reverse signals activating ERK–GST-π and NF-κB in tumor cells, and iRhom2 was identified as the upstream regulator of ADAM17-dependent TNF shedding in vivo.\",\n      \"evidence\": \"tmTNF NTF overexpression/knockdown with xenograft model; iRhom2 KO in lupus-prone mice with transcriptomic and pharmacological epistasis\",\n      \"pmids\": [\"29559745\", \"29369823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"structural basis of reverse signaling through tmTNF intracellular domain unknown\", \"iRhom2 regulation of TACE substrate selectivity not fully defined\", \"reverse signaling findings from single laboratory\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Co-stimulation with TNF and IFN-γ was shown to induce PANoptosis (combined pyroptosis, apoptosis, necroptosis) via JAK/STAT1/IRF1 and iNOS-dependent NO production, with dual cytokine neutralization protecting against SARS-CoV-2, sepsis, and HLH in mice.\",\n      \"evidence\": \"Cytokine co-treatment, pathway inhibitors, caspase-8/FADD KO, iNOS inhibitor, neutralizing antibodies in multiple mouse models\",\n      \"pmids\": [\"33278357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PANoptosis concept and its distinction from sequential independent death pathways still debated\", \"human clinical translation of dual neutralization not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of MLKL pore formation versus ion-channel activation at the plasma membrane; how transmembrane TNF reverse signaling is transduced through its short intracellular domain; the receptor subtype and downstream pathway mediating glial TNF-dependent synaptic scaling; and whether PANoptosis represents a mechanistically unified pathway or convergent activation of parallel death programs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"MLKL membrane pore versus channel activation mechanism unresolved\", \"structural basis of tmTNF reverse signaling unknown\", \"TNF receptor subtype for synaptic scaling not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 12, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 27, 28, 29]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 6, 16]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 3, 4, 14, 18, 19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 14, 15, 19, 20, 23, 24, 25, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 12, 21, 30]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [\n      \"TNFR1 complex I (TNFR1–TRADD–RIP1–TRAF2)\",\n      \"TNFR1 complex II (TRADD–RIP1–FADD–caspase-8)\",\n      \"RIP1–RIP3 necrosome\"\n    ],\n    \"partners\": [\n      \"TNFRSF1A\",\n      \"TNFRSF1B\",\n      \"TRADD\",\n      \"TRAF2\",\n      \"RIPK1\",\n      \"RIPK3\",\n      \"ADAM17\",\n      \"MLKL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}